var docs;if (!docs) docs =[]; docs["110"]={"11019":"<p><b>Title</b> Lurasidone / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lurasidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased lurasidone effects if combined with moderate CYP3A4 inducers. Consider increasing the lurasidone dose if coadministered with a moderate CYP3A4 inducer for 7 or more days.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> Although the effect of a moderate CYP3A4 inducer on lurasidone pharmacokinetics has not been studied, the strong CYP3A4 inducer rifampin (600 mg daily x 8 days) decreased the lurasidone (40 mg single dose) AUC and maximum serum concentration approximately 81% and 85%, respectively.<sup>1,2</sup> <br><br>Lurasidone prescribing information states that an increase in the lurasidone dose may be required when moderate CYP3A4 inducers and lurasidone are coadministered for 7 or more days.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; January 2017.</p>\n<p>2. Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. <i>Drug Metabol Drug Interact</i>. 2014;29(3):191-202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24825095\">[PubMed 24825095]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11020":"<p><b>Title</b> Anti-Parkinson Agents (Dopamine Agonist) / Sulpiride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Sulpiride may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of sulpiride and anti-Parkinson agents. This combination is specifically contraindicated in sulpiride product labeling.</p>\n<div>\n <p><b>Anti-Parkinson Agents (Dopamine Agonist) Interacting Members</b> Amantadine, Apomorphine, Bromocriptine, Levodopa, Pergolide, Piribedil, Pramipexole, ROPINIRole, Rotigotine</p>\n</div> \n<p><b>Discussion</b> According to the summary of product characteristics for several sulpiride brands, concurrent use with anti-Parkinson agents is contraindicated.<sup>1,2</sup> <br><br>The concern with the combination is that anti-Parkinson agents (dopamine precursor/dopamine receptor agonist) and sulpiride (which acts at least in part as a dopamine receptor antagonist) may antagonize each other's actions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dolmatil (sulpiride) [summary of product characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; March 2016.</p>\n<p>2. Dogmatil (sulpiride) [summary of product characteristics]. Gentilly, France: Sanofi Aventis France; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11021":"<p><b>Title</b> Propiverine / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The anticipated significance of this interaction is greater in patients also receiving methimazole.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propiverine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action is normally required when this combination is used. Start at the lowest recommended propiverine dose in patients receiving both a strong CYP3A4 inhibitor and methimazole, and monitor patients receiving these combinations for evidence of propiverine toxicity.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Propiverine product labeling states that it should be started at the lowest recommended dose in patients receiving both a strong CYP3A4 inhibitor and methimazole.<sup>1,2,3</sup> The suspected mechanism of this interaction is inhibition of propiverine metabolism via CYP3A4 and flavin-containing monooxygenases (by methimazole).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Detrunorm (propiverine) tablets [summary of product characteristics]. London, United Kingdom: Amdipharm UK Limited; August 2014.</p>\n<p>2. Detrunorm XL (propiverine) modified-release capsules [summary of product characteristics]. London, United Kingdom: Amdipharm UK Limited; June 2014.</p>\n<p>3. Mictoryl (propiverine) [product monograph]. Blainville, Quebec, Canada: Duchesnay Inc; December 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11022":"<p><b>Title</b> Tolperisone / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased risk of hypersensitivity reactions if tolperisone is combined with nonsteroidal anti-inflammatory drugs (NSAIDs). Additionally, lower doses of NSAIDs may achieve adequate analgesia when combined with tolperisone.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Tolperisone prescribing information and a saftey review conducted by the European Medicines Agency states that tolperisone use is associated with the development of hypersensitivity reactions and use of nonsteroidal anti-inflammatory drugs (NSAIDs) along with tolperisone may increase this risk.<sup>1,2,3</sup> In support of this finding, one case report describes a man who experienced a hypersensitivity reaction (eg pruritus, erythema, facial edema) after receiving tolperisone and the NSAIDs diclofenac and meloxicam.<sup>4</sup><br><br>In addition to an increased risk of hypersensitivity with this combination, tolperisone product labeling states that tolperisone may enhance the therapeutic effect of NSAIDs.<sup>1,2</sup> Two studies report that reduced doses of NSAIDs achieved similar analgesic efficacy as higher doses when combined with tolperisone.<sup>5,6</sup> <br><br>The mechanism of these interactions is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mydocalm (tolperisone hydrochloride) [prescribing information] Meyrin, Switzerland: Labatec Pharma SA; October 2013. </p>\n<p>2. Annex III relevant sections of the summary of product characteristics and package leaflet. Mydocalm (tolperisone hydrochloride) [prescribing information] Meyrin, Switzerland: Labatec Pharma SA; October 2013.</p>\n<p>3. European Medicines Agency: EMA/753061/2012. Assessment report for tolperisone containing medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Tolperisone_31/WC500141050.pdf, January 2013.</p>\n<p>4. Gluck J, Rymarczyk B, Rogala B. An immediate hypersensitivity reaction caused by tolperisone hydrochloride. <i>J Investig Allergol Clin Immunol</i>. 2011:21(5):411-412. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21905508\">[PubMed 21905508]</a></p>\n<p>5. Perenyi G. Combined drug treatment of neurological inflammatory processes. <i>Ther Hung</i>. 1981:29(4):186-190. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7188145\">[PubMed 7188145]</a></p>\n<p>6. Domotor E. Clinical examination of the synergistic effect of niflumic acid and tolperisone in genicular arthritis. <i>Ther Hung</i>. 1979:27(3):129-133. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=531773\">[PubMed 531773]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11023":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / Tolperisone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Tolperisone may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Ajmaline, Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Dapoxetine, Desipramine, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Indoramin, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tamoxifen, Tetrabenazine, Thioridazine, Timolol (Ophthalmic), Timolol (Systemic), Tolterodine, Trimipramine, Tropisetron, Venlafaxine, Vortioxetine, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Tolperisone prescribing information states that pharmacokinetic studies with dextromethorphan suggest that serum concentrations of CYP2D6 substrates may be increased when coadministered with tolpersisone.<sup>1,2</sup> However, the details of these studies are not available, and the published in vitro evidence suggests that tolperisone is not a clinically relevant CYP2D6 inhibitor.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013. </p>\n<p>2. Annex III relevant sections of the summary of product characteristics and package leaflet. Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013.</p>\n<p>3. Dalmadi B, Leibinger J, Szeberenyi S, et al. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. <i>Drug Metab Dispos</i>. 2003:31(5):631-636. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12695352\">[PubMed 12695352]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11024":"<p><b>Title</b> Muscle Relaxants (Centrally Acting) / Tolperisone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tolperisone may enhance the adverse/toxic effect of Muscle Relaxants (Centrally Acting). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased sedation or CNS effects if tolperisone is combined with other centrally acting muscle relaxants. Consider decreasing the tolperisone dose if these agents are combined.</p>\n<div>\n <p><b>Muscle Relaxants (Centrally Acting) Interacting Members</b> Baclofen, Carisoprodol, Chlorzoxazone, Cyclobenzaprine, Metaxalone, Methocarbamol, Orphenadrine</p>\n</div> \n<p><b>Discussion</b> Although the potential for tolperisone to cause sedation is minimal,<sup>1,2</sup>, tolperisone prescribing information states that a dose reduction of tolperisone should be considered if it is combined with other centrally acting muscle relaxants.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Annex III relevant sections of the summary of product characteristics and package leaflet. Mydocalm (tolperisone hydrochloride) [prescribing information] Meyrin, Switzerland: Labatec Pharma SA; October 2013.</p>\n<p>2. Dulin J, Kovacs L, Ramm S, Horvath F, Ebeling L, Kohnen R. Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, randomized, double-blind, placebo-controlled trial. <i>Pharmacopsychiatry</i>. 1998:31(4):137-142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9754848\">[PubMed 9754848]</a></p>\n<p>3. Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11025":"<p><b>Title</b> Sertraline / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Sertraline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of sertraline if combined with carbamazepine.</p> \n<p><b>Discussion</b> In a retrospective analysis of patients taking sertraline, those who received sertraline monotherapy (54 patients) had a 3.12-fold higher concentration-to-daily dose ratio compared with patients who received sertraline with either carbamazepine or phenytoin (9 patients).<sup>1</sup> A case report describes 2 patients who, despite increasing sertraline doses up to 300 mg per day, experienced undetectable sertraline serum concentrations and a lack of sertraline efficacy when added to stable carbamazepine therapy.<sup>2</sup> <br><br>A separate case report describes a female patient stabilized on carbamazepine (600 mg per day for 2 years) who experienced a 1.81-fold increase in carbamazepine serum trough levels and bone marrow suppression after initiation of sertraline (100 mg daily).<sup>3</sup> In contrast, 3 pharmacokinetic studies of healthy volunteers found that sertraline (50 mg to 200 mg daily) had no effect on the pharmacokinetic parameters of carbamazepine.<sup>4,5,6</sup> <br><br>Carbamazepine prescribing information states that serum levels of sertraline may be reduced when coadministered with carbamazepine.<sup>7</sup> Sertraline prescribing information states that sertraline’s inhibition of CYP3A4 is not clinically significant, and it does not appear to increase plasma concentrations of CYP3A4 substrates such as carbamazepine.<sup>8</sup><br><br>The mechanism by which carbamazepine reduces sertraline concentrations is likely due to carbamazepine induction of CYP3A4, thus increasing the metabolism of CYP3A4 substrates such as sertraline. The single case report describing increased carbamazepine concentrations with the addition of sertraline may be due to other variables (eg, compliance, changes in clinical status of the patient, other unreported concomitant medications), as the majority of data suggests that sertraline does not inhibit CYP3A4 or affect the pharmacokinetics of carbamazepine.<sup>4,5,6,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pihlsgard M, Eliasson E. Significant reduction of sertraline plasma levels by carbamazepine and phenytoin. <i>Eur J Clin Pharmacol</i>. 2002:57(12):915-916. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936714\">[PubMed 11936714]</a></p>\n<p>2. Khan A, Shad MU, Preskorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine. <i>J Clin Psychiatry</i>. 2006:61(7):526-527. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10937612\">[PubMed 10937612]</a></p>\n<p>3. Joblin M. Possible interaction of sertraline with carbamazepine. <i>N Z Med J</i>. 1994:107(97):43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8043067\">[PubMed 8043067]</a></p>\n<p>4. Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K. Absence of sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. <i>J Clin Psychiatry</i>. 1996:57(suppl 1):20-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8617707\">[PubMed 8617707]</a></p>\n<p>5. Preskorn SH, Alderman J, Greenblatt DJ, Horst WD. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. <i>Psychopharmacol Bull</i>. 1997:33(4):659-665. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9493476\">[PubMed 9493476]</a></p>\n<p>6. Lane RM. Carbamazepine and sertraline. <i>N Z Med J</i>. 1994:107(978):209. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8196873\">[PubMed 8196873]</a></p>\n<p>7. Tegretol XR (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p>8. Zolft (sertraline hydrochloride) [prescribing information]. New York, NY: Pfizer Inc; December 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11026":"<p><b>Title</b> QTc-Prolonging Agents (Highest Risk) / Propiverine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Propiverine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Highest Risk) Interacting Members</b> Ajmaline, Amiodarone, Anagrelide, Arsenic Trioxide, Artemether, Asenapine, Astemizole, Bepridil, Cisapride, Citalopram, Deutetrabenazine, Disopyramide, Dofetilide, Domperidone, Dosulepin, Dronedarone, Eliglustat, FLUoxetine, Flupentixol, Halofantrine, Ibutilide, Iloperidone, Lopinavir, Lumefantrine, MiFEPRIStone, Nilotinib, Paliperidone, Pimavanserin, Pimozide, Pipamperone [INT], Procainamide, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ribociclib, Sotalol, Sparfloxacin, Sulpiride, Terfenadine, Tetrabenazine, Thioridazine, Toremifene, Vandetanib, Vemurafenib, Vernakalant, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Propiverine product labeling states that a thorough QT interval study has not been conducted in patients taking propiverine, but cautions on its potential to cause QT prolongation based on reports that other antimuscarinic agents have been associated with QT prolongation.<sup>1</sup> In contrast to this warning, in a study conducted in 98 patients randomized to propiverine (15 mg three times daily for 4 weeks) or placebo, no significant differences in QT/QTc interval changes between the groups were found.<sup>2</sup> Additionally, an in vitro study suggests that the cardiovascular risk of propiverine is low.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mictoryl (propiverine) [product monograph]. Blainville, Quebec, Canada: Duchesnay Inc; December 2016.</p>\n<p>2. Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients-a double-blind, placebo-controlled clinical study. <i>Eur Urol</i>. 2000:37(6):702-708. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10828671\">[PubMed 10828671]</a></p>\n<p>3. Christ T, Wettwer E, Wuest M, et al. Electrophysiological profile of propiverine-relationship to cardiac risk. <i>Naunyn Schmiedebergs Arch Pharmacol</i>. 2008:376(6):431-440. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18092154\">[PubMed 18092154]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11027":"<p><b>Title</b> QTc-Prolonging Agents (Moderate Risk) / Propiverine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Propiverine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Moderate Risk) Interacting Members</b> Azithromycin (Systemic), Bedaquiline, Benperidol, Ceritinib, Chloroquine, ChlorproMAZINE, Ciprofloxacin (Systemic), Clarithromycin, Clofazimine, CloZAPine, Crizotinib, Delamanid, Dolasetron, Droperidol, Efavirenz, Erythromycin (Systemic), Escitalopram, Flecainide, Gadobenate Dimeglumine, Gemifloxacin, Goserelin, Granisetron, Haloperidol, Inotuzumab Ozogamicin, Lenvatinib, Leuprolide, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lofexidine, Mequitazine, Methadone, Midostaurin, Moxifloxacin (Systemic), Ofloxacin (Systemic), OLANZapine, Ondansetron, Osimertinib, Panobinostat, PAZOPanib, Pentamidine (Systemic), Pilsicainide, Piperaquine, Primaquine, Probucol, Propafenone, RisperiDONE, Roxithromycin, Saquinavir, Sodium Stibogluconate, Telavancin, Telithromycin, Terlipressin</p>\n</div> \n<p><b>Discussion</b> Propiverine product labeling states that a thorough QT interval study has not been conducted in patients taking propiverine, but cautions on its potential to cause QT prolongation based on reports that other antimuscarinic agents have been associated with QT prolongation.<sup>1</sup> In contrast to this warning, in a study conducted in 98 patients randominzed to propiverine (15 mg three times daily for 4 weeks) or placebo, no significant differences in QT/QTc interval changes between the groups were found.<sup>2</sup> Additionally, an in vitro study suggests that the cardiovascular risk of propiverine is low.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mictoryl (propiverine) [product monograph]. Blainville, Quebec, Canada: Duchesnay Inc; December 2016.</p>\n<p>2. Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients-a double-blind, placebo-controlled clinical study. <i>Eur Urol</i>. 2000:37(6):702-708. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10828671\">[PubMed 10828671]</a></p>\n<p>3. Christ T, Wettwer E, Wuest M, et al. Electrophysiological profile of propiverine-relationsihp to cardiac risk. <i>Naunyn Schmiedebergs Arch Pharmacol</i>. 2008:376(6):431-440. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18092154\">[PubMed 18092154]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11028":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Zaltoprofen</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Zaltoprofen may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of zaltoprofen and other nonsteroidal anti-inflammatory drugs.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Zaltoprofen product labeling states that the concomitant use of zaltoprofen and other nonsteroidal anti-inflammatory drugs may increase the risk for adverse events and should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Soleton (zaltoprofen) tablets [KR prescribing information). http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199701525. Accessed May 8, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11029":"<p><b>Title</b> CycloSPORINE (Systemic) / Probucol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probucol may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased cyclosporine concentrations and effects if combined with probucol.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 6 heart transplant patients stabilized on cyclosporine therapy (average dose 180 mg twice daily) the cyclosporine AUC, whole blood concentration trough, and the plasma trough decreased 43%, 34%, and 42%, respectively, when coadministered with probucol (500 mg twice daily).<sup>1</sup> In a pharmacokinetic study of 10 renal transplant patients stabilized on cyclosporine therapy (average dose 5.6 mg/kg/day), the cyclosporine whole blood concentration trough and the trough concentration of cyclosporine plus metabolites in the plasma decreased 23% and 48%, respectively, when coadministered with probucol (500 mg daily).<sup>2</sup> <br><br>The mechanism of this interaction is unknown, however, authors of one study suggest that alterations in lipid concentrations caused by probucol could alter the distribution of cyclosporine because it is 40% to 60% bound to cholesterol rich lipoproteins.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sundararajan V, Cooper DK, Muchmore J, et al. Interaction of cyclosporine and probucol in heart transplant patients. <i>Transplant Proc</i>. 1991;23(3):2028-2032. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2063476\">[PubMed 2063476]</a></p>\n<p>2. Gallego C, Sanchez P, Planells C, et al. Interaction between probucol and cyclosporine in renal transplant patients. <i>Ann Pharmacother</i>. 1994;28(7-8):940-943. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7949516\">[PubMed 7949516]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11030":"<p><b>Title</b> QTc-Prolonging Agents (Highest Risk) / Probucol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Probucol may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of probucol with any highest risk QTc-prolonging agent should be avoided. Concomitant use is expected to substantially increase the risk for QTc prolongation, the development of torsades de pointes, or other significant ventricular tachyarrhythmias. Patients with other risk factors present (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease) may be at an even higher risk for these potentially life-threatening toxicities.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Highest Risk) Interacting Members</b> Ajmaline, Amiodarone, Anagrelide, Arsenic Trioxide, Artemether, Asenapine, Astemizole, Bepridil, Cisapride, Citalopram, Deutetrabenazine, Disopyramide, Dofetilide, Domperidone, Dosulepin, Dronedarone, Eliglustat, FLUoxetine, Flupentixol, Halofantrine, Ibutilide, Iloperidone, Lopinavir, Lumefantrine, MiFEPRIStone, Nilotinib, Paliperidone, Pimavanserin, Pimozide, Pipamperone [INT], Procainamide, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ribociclib, Sotalol, Sparfloxacin, Sulpiride, Terfenadine, Tetrabenazine, Thioridazine, Toremifene, Vandetanib, Vemurafenib, Vernakalant, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Several studies have evaluated the effect of probucol on the QTc interval.<sup>1,2,3,4,5,6,7,8,9,10,11</sup> While some have found negligible or very modest increases in the mean QTc interval with probucol administration (3 to 10 msec),<sup>2,3,5,6,7</sup> others have reported more significant increases in the QTc interval (16 to 38 msec).<sup>1,3,4,5,8,9,10,11</sup> Increasing probucol concentrations have been correlated with increased QTc length in some,<sup>3,8</sup> but not all,<sup>4,5,10</sup> studies. Additionally, several case reports of probucol associated QTc interval prolongation have been described.<sup>12,13,14</sup><br><br>Probucol product labeling states that coadministration of probucol with another QTc-prolonging agent may increase the risk of QTc prolongation and ventricular arrhythmias, and that such combinations should be avoided.<sup>15</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ohya Y, Kumamoto K, Abe I, Tsubota Y, Fujishima M. Factors related to QT interval prolongation during probucol treatment. <i>Eur J Clin Pharmacol</i>. 1993;45(1):47-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8405029\">[PubMed 8405029]</a></p>\n<p>2. Dujovne CA, Atkins F, Wong B, DeCoursey S, Krehbiel P, Chernoff SB. Electrocardiographic effects of probucol. A controlled prospective trial. <i>Eur J Clin Pharmacol</i>. 1984;26(6):735-739. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6386485\">[PubMed 6386485]</a></p>\n<p>3. Troendle G, Guerigian J, Sobel S, Johnson M. Probucol and the QT interval. <i>Lancet</i>. 1982;1(8282):1179. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6122949\">[PubMed 6122949]</a></p>\n<p>4. McCaughan D. Probucol and the QT interval. <i>Lancet</i>. 1982;2(8290):161. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6123876\">[PubMed 6123876]</a></p>\n<p>5. Martz B. Probucol and the QT interval. <i>Lancet</i>. 1982;1(8285):1365. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6123673\">[PubMed 6123673]</a></p>\n<p>6. Polachek AA, Katz HM, Sack J, Selig J, Littman ML. Probucol in the long-term treatment of hypercholesterolaemia. <i>Curr Med Res Opin</i>. 1973;1(6):323-330. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4589404\">[PubMed 4589404]</a></p>\n<p>7. Kosasayama A, Yoshida M, Okada S. Post-marketing surveillance of probucol (Sinlestal) in Japan. <i>Artery</i>. 1992;19(3):147-161. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1637256\">[PubMed 1637256]</a></p>\n<p>8. Browne KF, Prystowsky EN, Heger JJ, Cerimele BJ, Fineberg N, Zipes DP. Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug. <i>Am Heart J</i>. 1984;107(4):680-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6702562\">[PubMed 6702562]</a></p>\n<p>9. Jones DB, Simpson HC, Slaughter P, et al. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia. <i>Atherosclerosis</i>. 1984;53(1):1-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6388586\">[PubMed 6388586]</a></p>\n<p>10. Sasaki N, Saku K, Moroe K, et al. Long-term administration of probucol and QTc interval prolongation. <i>Artery</i>. 1993;20(2):115-121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8512458\">[PubMed 8512458]</a></p>\n<p>11. Graham I, Ronan G, Comerford D, Hickey N, Daly L, Mulcahy R. Probucol, blood lipids and the ECG QTc interval. <i>Ir Med J</i>. 1986;79(2):45-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3733408\">[PubMed 3733408]</a></p>\n<p>12. Tamura M, Ueki Y, Ohtsuka E, et al. Probucol-induced QT prolongation and syncope. <i>Jpn Circ J</i>. 1994;58(5):374-377. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8022053\">[PubMed 8022053]</a></p>\n<p>13. Matsuhashi H, Onodera S, Kawamura Y, et al. Probucol-induced QT prolongation and torsades de pointes. <i>Jpn J Med</i>. 1989;28(5):612-615. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2585889\">[PubMed 2585889]</a></p>\n<p>14. Gohn DC, Simmons TW. Polymorphic ventricular tachycardia (Torsade de Pointes) associated with the use of probucol. <i>N Engl J Med</i>. 1992;326(21):1435-1436. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1569995\">[PubMed 1569995]</a></p>\n<p>15. Probucol tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200707005. Accessed October 24, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11031":"<p><b>Title</b> QTc-Prolonging Agents (Moderate Risk) / Probucol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Probucol may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of probucol with any moderate risk QTc-prolonging agent should be avoided. Concomitant use is expected to substantially increase the risk for QTc prolongation, the development of torsades de pointes, or other significant ventricular tachyarrhythmias. Patients with other risk factors present (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease) may be at an even higher risk for these potentially life-threatening toxicities.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Moderate Risk) Interacting Members</b> Azithromycin (Systemic), Bedaquiline, Benperidol, Ceritinib, Chloroquine, ChlorproMAZINE, Ciprofloxacin (Systemic), Clarithromycin, Clofazimine, CloZAPine, Crizotinib, Delamanid, Dolasetron, Droperidol, Efavirenz, Erythromycin (Systemic), Escitalopram, Flecainide, Gadobenate Dimeglumine, Gemifloxacin, Goserelin, Granisetron, Haloperidol, Inotuzumab Ozogamicin, Lenvatinib, Leuprolide, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lofexidine, Mequitazine, Methadone, Midostaurin, Moxifloxacin (Systemic), Ofloxacin (Systemic), OLANZapine, Ondansetron, Osimertinib, Panobinostat, PAZOPanib, Pentamidine (Systemic), Pilsicainide, Piperaquine, Primaquine, Probucol, Propafenone, RisperiDONE, Roxithromycin, Saquinavir, Sodium Stibogluconate, Telavancin, Telithromycin, Terlipressin</p>\n</div> \n<p><b>Discussion</b> Several studies have evaluated the effect of probucol on the QTc interval.<sup>1,2,3,4,5,6,7,8,9,10,11</sup> While some have found negligible or very modest increases in the mean QTc interval with probucol administration (3 to 10 msec),<sup>2,3,5,6,7</sup> others have reported more significant increases in the QTc interval (16 to 38 msec).<sup>1,3,4,5,8,9,10,11</sup> Increasing probucol concentrations have been correlated with increased QTc length in some,<sup>3,8</sup> but not all,<sup>4,5,10</sup> studies. Additionally, several case reports of probucol associated QTc interval prolongation have been described.<sup>12,13,14</sup><br><br>Probucol product labeling states that coadministration of probucol with another QTc-prolonging agent may increase the risk of QTc prolongation and ventricular arrhythmias, and that such combinations should be avoided.<sup>15</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ohya Y, Kumamoto K, Abe I, Tsubota Y, Fujishima M. Factors related to QT interval prolongation during probucol treatment. <i>Eur J Clin Pharmacol</i>. 1993;45(1):47-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8405029\">[PubMed 8405029]</a></p>\n<p>2. Dujovne CA, Atkins F, Wong B, DeCoursey S, Krehbiel P, Chernoff SB. Electrocardiographic effects of probucol. A controlled prospective trial. <i>Eur J Clin Pharmacol</i>. 1984;26(6):735-739. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6386485\">[PubMed 6386485]</a></p>\n<p>3. Troendle G, Guerigian J, Sobel S, Johnson M. Probucol and the QT interval. <i>Lancet</i>. 1982;1(8282):1179. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6122949\">[PubMed 6122949]</a></p>\n<p>4. McCaughan D. Probucol and the QT interval. <i>Lancet</i>. 1982;2(8290):161. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6123876\">[PubMed 6123876]</a></p>\n<p>5. Martz B. Probucol and the QT interval. <i>Lancet</i>. 1982;1(8285):1365. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6123673\">[PubMed 6123673]</a></p>\n<p>6. Polachek AA, Katz HM, Sack J, Selig J, Littman ML. Probucol in the long-term treatment of hypercholesterolaemia. <i>Curr Med Res Opin</i>. 1973;1(6):323-330. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4589404\">[PubMed 4589404]</a></p>\n<p>7. Kosasayama A, Yoshida M, Okada S. Post-marketing surveillance of probucol (Sinlestal) in Japan. <i>Artery</i>. 1992;19(3):147-161. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1637256\">[PubMed 1637256]</a></p>\n<p>8. Browne KF, Prystowsky EN, Heger JJ, Cerimele BJ, Fineberg N, Zipes DP. Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug. <i>Am Heart J</i>. 1984;107(4):680-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6702562\">[PubMed 6702562]</a></p>\n<p>9. Jones DB, Simpson HC, Slaughter P, et al. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia. <i>Atherosclerosis</i>. 1984;53(1):1-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6388586\">[PubMed 6388586]</a></p>\n<p>10. Sasaki N, Saku K, Moroe K, et al. Long-term administration of probucol and QTc interval prolongation. <i>Artery</i>. 1993;20(2):115-121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8512458\">[PubMed 8512458]</a></p>\n<p>11. Graham I, Ronan G, Comerford D, Hickey N, Daly L, Mulcahy R. Probucol, blood lipids and the ECG QTc interval. <i>Ir Med J</i>. 1986;79(2):45-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3733408\">[PubMed 3733408]</a></p>\n<p>12. Tamura M, Ueki Y, Ohtsuka E, et al. Probucol-induced QT prolongation and syncope. <i>Jpn Circ J</i>. 1994;58(5):374-377. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8022053\">[PubMed 8022053]</a></p>\n<p>13. Matsuhashi H, Onodera S, Kawamura Y, et al. Probucol-induced QT prolongation and torsades de pointes. <i>Jpn J Med</i>. 1989;28(5):612-615. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2585889\">[PubMed 2585889]</a></p>\n<p>14. Gohn DC, Simmons TW. Polymorphic ventricular tachycardia (Torsade de Pointes) associated with the use of probucol. <i>N Engl J Med</i>. 1992;326(21):1435-1436. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1569995\">[PubMed 1569995]</a></p>\n<p>15. Probucol tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200707005. Accessed October 24, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11032":"<p><b>Title</b> Flibanserin / CYP2C19 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased flibanserin toxicities (eg, hypotension, syncope, CNS depression) if combined with a moderate CYP2C19 inhibitor.</p>\n<div>\n <p><b>CYP2C19 Inhibitors (Moderate) Interacting Members</b> FLUoxetine, FluvoxaMINE, Moclobemide, Stiripentol, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacogenomic study described in the flibanserin prescribing information, 9 women who were poor CYP2C19 metabolizers had an average flibanserin AUC and maximum serum concentration (Cmax) that was 1.3-fold and 1.5-fold higher compared with 8 women who were extensive CYP2C19 metabolizers.<sup>1</sup> Syncope occurred in 1 poor metabolizer who was found to have a 3.2-fold higher flibanserin AUC compared with extensive CYP2C19 metabolizers. No syncope was reported in the extensive metabolizer group.<sup>1</sup> In another study of 15 healthy volunteers, fluconazole (400 mg single dose, then 200 mg daily for 5 days) increased the flibanserin (100 mg single dose) AUC and Cmax 7-fold and 2.2-fold, respectively.<sup>1</sup> Hypotension or syncope occurred in 3 patients (20%) and the study was terminated early.<sup>1</sup> <br><br>Prescribing information for flibanserin states that concomitant use of flibanserin with strong CYP2C19 inhibitors may increase flibanserin exposure and increase the risk for syncope, hypotension, and CNS depression.<sup>1</sup> Patients should be informed of this risk if these agents are combined and should be monitored closely for these adverse effects.<sup>1</sup><br><br>Because flibanserin is partially metabolized by CYP2C19, inhibition of CYP2C19 or the presence of a poor CYP2C19 metabolizer genotype likely leads to increased exposure and effects. The magnitude of this interaction will likely be greater with drugs that inhibit multiple CYP enzymes involved in flibanserin metabolism (ie, fluconazole) compared with those that exclusively inhibit CYP2C19.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11033":"<p><b>Title</b> Antihypertensive Agents / Oxymetazoline (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Oxymetazoline (Topical) may diminish the therapeutic effect of Antihypertensive Agents. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antihypertensive Agents Interacting Members</b> Acebutolol, Alacepril, Aliskiren, AMILoride, AmLODIPine, Arotinolol, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bumetanide, Candesartan, Captopril, Carvedilol, Celiprolol, Chlorothiazide, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, CloNIDine, Cyclopenthiazide, DilTIAZem, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Imidapril, Indapamide, Indoramin, Irbesartan, Isradipine, Labetalol, Lacidipine, Lercanidipine, Lisinopril, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Moxonidine, Nadolol, Nebivolol, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitroprusside, Olmesartan, Oxprenolol, Penbutolol, Perindopril, Phenoxybenzamine, Phentolamine, Pindolol, Prazosin, Propranolol, Quinapril, Ramipril, Reserpine, Rilmenidine, Spironolactone, Telmisartan, Terazosin, Timolol (Systemic), Torsemide, Trandolapril, Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Prescribing information for topical oxymetazoline states that because oxymetazoline is an alpha1-agonist, it may diminish or negate the effects antihypertensive agents, since they exert opposing effects on vascular tone and blood pressure.<sup>1</sup> However, topical oxymetazoline achieves systemic concentrations over 100 times lower than those achieved with nasal administration, so the risk of a clinically significant interaction may be minimal.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rhofade (oxymetazoline) cream [prescribing information]. Irvine, CA: Allergan; January 2017.</p>\n<p>2. Kovanaze (tetracaine and oxymetazoline) nasal spray [prescribing information]. Fort Collins, CO: St. Renatus LLC; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11034":"<p><b>Title</b> Alpha1-Blockers / Oxymetazoline (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Oxymetazoline (Topical) may diminish the therapeutic effect of Alpha1-Blockers. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Alpha1-Blockers Interacting Members</b> Alfuzosin, Doxazosin, Indoramin, Moxisylyte, Naftopidil, Nicergoline, Phenoxybenzamine, Phentolamine, Prazosin, Silodosin, Tamsulosin, Terazosin</p>\n</div> \n<p><b>Discussion</b> Prescribing information for topical oxymetazoline states that because oxymetazoline is an alpha1-agonist, it may diminish or negate the effects of alpha1-blockers, since they exert opposing effects on vascular tone and blood pressure.<sup>1</sup> However, topical oxymetazoline achieves systemic concentrations over 100 times lower than those achieved with nasal administration, so the risk of a clinically significant interaction may be minimal.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rhofade (oxymetazoline) cream [prescribing information]. Irvine, CA: Allergan; January 2017.</p>\n<p>2. Kovanaze (tetracaine and oxymetazoline) nasal spray [prescribing information]. Fort Collins, CO: St. Renatus LLC; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11035":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Oxymetazoline (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Oxymetazoline (Topical) may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Prescribing information for topical oxymetazoline states that caution is advised in patients taking monoamine oxidase inhibitors (MAOIs). Because MAOIs can affect the metabolism and uptake of circulating amines, an exaggerated hypertensive effect may occur if these agents are combined.<sup>1</sup> However, topical oxymetazoline achieves systemic concentrations over 100 times lower than those achieved with nasal administration, so the risk of a clinically significant interaction may be minimal.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rhofade (oxymetazoline) cream [prescribing information]. Irvine, CA: Allergan; January 2017.</p>\n<p>2. Kovanaze (tetracaine and oxymetazoline) nasal spray [prescribing information]. Fort Collins, CO: St. Renatus LLC; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11036":"<p><b>Title</b> Neuromuscular-Blocking Agents / Bacitracin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bacitracin (Systemic) may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for prolonged/enhanced neuromuscular blockade during concomitant use of bacitracin and neuromuscular-blocking agents.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine, Vecuronium</p>\n</div> \n<p><b>Discussion</b> One case report describes a patient who experienced prolonged pancuronium-associated neuromuscular blockade after receiving a 1 liter surgical wound irrigation containing bacitracin (50,000 units) and polymyxin B (250,000 units).<sup>1</sup> Another report describes a patient who experienced respiratory paralysis requiring ventilator assistance after receiving an intraperitoneal instillation of bacitracin (100,000 units) and polymyxin B (100 mg).<sup>2</sup> <br><br>Although polymyxin B has a stronger association with neuromuscular blockade, the role of bacitracin in these cases cannot be excluded. As such, prescribing information for the majority of neuromuscular-blocking agents states that bacitracin may enhance the neuromuscular-blocking action of these drugs.<sup>3,4,5,6,7</sup> Prolonged or enhanced neuromuscular blockade may occur with this combination.<sup>3,4,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fogdall RP, Miller RD. Prolongation of a pancuronium-induced neuronmuscular blockade by polymyxin B. <i>Anesthesiology</i>. 1974;40(1):84-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4359101\">[PubMed 4359101]</a></p>\n<p>2. Small GA. Report of a case. Respiratory paralysis after a large dose of intraperitoneal polymyxin B and bacitracin. <i>Anesth Analg</i>. 1964;43:137-139. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14164930\">[PubMed 14164930]</a></p>\n<p>3. Mivacron (mivarcurium) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>4. Pavulon (pancuronium) [prescribing information]. West Orange, NJ: Organon Inc; November 2010.</p>\n<p>5. Nimbex (cisatracurium) [prescribing information]. Lake Forest, IL: Hospira Inc; November 2010.</p>\n<p>6. Zemuron (rocuronium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; January 2015. </p>\n<p>7. Vecuronium [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; July 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11037":"<p><b>Title</b> Neuromuscular-Blocking Agents / Local Anesthetics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for prolonged/enhanced neuromuscular blockade during concomitant use of local anesthetics and neuromuscular-blocking agents.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine, Vecuronium</p>\n <p><b>Local Anesthetics Interacting Members</b> Articaine, Benoxinate, Bupivacaine, Bupivacaine (Liposomal), Chloroprocaine, Levobupivacaine, Lidocaine (Systemic), Mepivacaine, Prilocaine, Procaine, Ropivacaine, Tetracaine (Systemic)<br><b>Exceptions</b> Benzocaine, Benzydamine, Cocaine (Topical), Dibucaine, Dyclonine, Ethyl Chloride, Hexylresorcinol, Lidocaine (Ophthalmic), Lidocaine (Topical), Pramoxine, Proparacaine, Tetracaine (Ophthalmic), Tetracaine (Topical)</p>\n</div> \n<p><b>Discussion</b> Two studies have reported that the neuromuscular blocking effects of mivacurium and rocuronium were enhanced and prolonged when combined with prilocaine or lidocaine.<sup>1,2</sup><br><br>Prescribing information for several neuromuscular-blocking agents states that local anesthetics may enhance the neuromuscular blocking action of these drugs and that prolonged or enhanced neuromuscular blockade may occur with this combination.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Torrance JM, Lewer BM, Galletly DC. Low-dose mivacurium supplementation of prilocaine i.v. regional anaesthesia. <i>Br J Anaesth</i>. 1997;78(2):222-223. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9068344\">[PubMed 9068344]</a></p>\n<p>2. Ninomiya A, Terakawa Y, Matsuura N, Ichinohe T, Kaneko Y. Oral mucosal injection of a local anesthetic solution containing epinephrine enhances muscle relaxant effects of rocuronium. <i>Anesth Prog</i>. 2012;59(1):18-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22428970\">[PubMed 22428970]</a></p>\n<p>3. Mivacron (mivarcurium) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>4. Nimbex (cisatracurium) [prescribing information]. Lake Forest, IL: Hospira Inc; November 2010.</p>\n<p>5. Zemuron (rocuronium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11038":"<p><b>Title</b> Simvastatin / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider using a non-interacting HMG-CoA reductase inhibitor (eg, pravastatin, pitavastatin) in patients receiving amiodarone. If these drugs are combined, limit the simvastatin dose to 20 mg daily and monitor for evidence of simvastatin toxicities (eg, myalgia, liver function test elevations, rhabdomyolysis).</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 12 healthy volunteers, the AUC, maximum serum concentration, and elimination half-life of simvastatin (40 mg single dose) increased 73%, 100%, and 48%, respectively, after coadministration with amiodarone (400mg/day x 3 days).<sup>1</sup> Several case reports describe patients taking simvastatin (40 to 80 mg daily) who developed severe simvastatin toxicities (eg, rhabdomyolysis, myopathy, myositis, acute renal failure) after initiation of amiodarone.<sup>2,3,4</sup> Other reports describe patients taking amiodarone who experienced simvastatin toxicities after initiation or dose escalation of simvastatin.<sup>5,6</sup> Two other case reports also describe simvastatin muscle toxicities with the use of these agents, but the presence of other interacting drugs in one case,<sup>7</sup> and the onset of symptoms not being temporally related to either drug initiation in the other,<sup>8</sup> make the role of this drug interaction in these cases less clear. <br><br>Simvastatin and amiodarone prescribing information both state that due to the risk of statin-related muscle toxicities, including rhabdomyolysis, the dose of simvastatin should be limited to 20 mg daily if combined with amiodarone.<sup>9,10</sup><br><br>The mechanism of this interaction is likely due to amiodarone-mediated inhibition of CYP3A4, an enzyme responsible for simvastatin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Becquemont L, Neuvonen M, Verstuyft C, et al. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. <i>Clin Pharmacol Ther</i>. 2007;81(5):679-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17301736\">[PubMed 17301736]</a></p>\n<p>2. Marot A, Morelle J, Chouinard VA, Jadoul M, Lambert M, Demoulin N. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. <i>Acta Clin Belg</i>. 2011;66(2):134-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21630612\">[PubMed 21630612]</a></p>\n<p>3. Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. <i>J Am Board Fam Med</i>. 2007;20(4):411-416. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17615423\">[PubMed 17615423]</a></p>\n<p>4. Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. <i>Ann Pharmacother</i>. 2004;38(6):978-981. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15069169\">[PubMed 15069169]</a></p>\n<p>5. Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. <i>Ann Pharmacother</i>. 2006;40(4):753-757. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16537817\">[PubMed 16537817]</a></p>\n<p>6. Wratchford P, Ponte CD. High-dose simvastatin and rhabdomyolysis. <i>Am J Health Syst Pharm</i>. 2003;60(7):698-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12701554\">[PubMed 12701554]</a></p>\n<p>7. Chouhan UM, Chakrabarti S, Millward LJ. Simvastatin interaction with clarithromycin and amiodarone causing myositis. Ann Pharmacother. 2005:39(10):1760-1761. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16159992\">[PubMed 16159992]</a></p>\n<p>8. Nagele H, Behrens S, Hashagen S, Azizi M. Rhabdomyolysis after addition of digitoxin to chronic simvastatin and amiodarone therapy. <i>Drug Metabol Drug Interact</i>. 2007;22(2-3):195-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17708069\">[PubMed 17708069]</a></p>\n<p>9. Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; March 2015.</p>\n<p>10. Cordarone (amiodarone) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11039":"<p><b>Title</b> Lovastatin / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of Lovastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using a non-interacting HMG-CoA reductase inhibitor (eg, pravastatin, pitavastatin) in patients receiving amiodarone. If these drugs are combined, limit the lovastatin dose to 40 mg daily and monitor for evidence of lovastatin toxicities (eg, myalgia, liver function test elevations, rhabdomyolysis).</p> \n<p><b>Discussion</b> Although no studies or case reports have documented an interaction between amiodarone and lovastatin, numerous reports describe an interaction between amiodarone and simvastatin, a similar CYP3A4 metabolized statin. In a pharmacokinetic study conducted in 12 healthy volunteers, the AUC, maximum serum concentration, and elimination half-life of simvastatin (40 mg single dose) increased 73%, 100%, and 48%, respectively, after coadministration with amiodarone (400 mg/day x 3 days).<sup>1</sup> Several case reports describe patients taking simvastatin (40 to 80 mg daily) who developed severe simvastatin toxicities (eg, rhabdomyolysis, myopathy, myositis, acute renal failure) after initiation of amiodarone.<sup>2,3,4</sup> Other reports describe patients taking amiodarone who experienced simvastatin toxicities after initiation or dose escalation of simvastatin.<sup>5,6</sup> Two other case reports also describe simvastatin muscle toxicities with the use of these agents, but the presence of other interacting drugs in one case,<sup>7</sup> and the onset of symptoms not being temporally related to either drug initiation in the other,<sup>8</sup> make the role of this drug interaction in these cases less clear. <br><br>Lovastatin and amiodarone prescribing information both state that due to the risk of statin-related muscle toxicities, including rhabdomyolysis, the dose of lovastatin should be limited to 40 mg daily if combined with amiodarone.<sup>9,10</sup><br><br>The mechanism of this interaction is likely due to amiodarone-mediated inhibition of CYP3A4, an enzyme responsible for lovastatin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Becquemont L, Neuvonen M, Verstuyft C, et al. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. <i>Clin Pharmacol Ther</i>. 2007;81(5):679-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17301736\">[PubMed 17301736]</a></p>\n<p>2. Marot A, Morelle J, Chouinard VA, Jadoul M, Lambert M, Demoulin N. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. <i>Acta Clin Belg</i>. 2011;66(2):134-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21630612\">[PubMed 21630612]</a></p>\n<p>3. Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. <i>J Am Board Fam Med</i>. 2007;20(4):411-416. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17615423\">[PubMed 17615423]</a></p>\n<p>4. Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. <i>Ann Pharmacother</i>. 2004;38(6):978-981. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15069169\">[PubMed 15069169]</a></p>\n<p>5. Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. <i>Ann Pharmacother</i>. 2006;40(4):753-757. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16537817\">[PubMed 16537817]</a></p>\n<p>6. Wratchford P, Ponte CD. High-dose simvastatin and rhabdomyolysis. <i>Am J Health Syst Pharm</i>. 2003;60(7):698-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12701554\">[PubMed 12701554]</a></p>\n<p>7. Chouhan UM, Chakrabarti S, Millward LJ. Simvastatin interaction with clarithromycin and amiodarone causing myositis. Ann Pharmacother. 2005:39(10):1760-1761. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16159992\">[PubMed 16159992]</a></p>\n<p>8. Nagele H, Behrens S, Hashagen S, Azizi M. Rhabdomyolysis after addition of digitoxin to chronic simvastatin and amiodarone therapy. <i>Drug Metabol Drug Interact</i>. 2007;22(2-3):195-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17708069\">[PubMed 17708069]</a></p>\n<p>9. Mevacor (lovastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2014.</p>\n<p>10. Cordarone (amiodarone) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11040":"<p><b>Title</b> Red Yeast Rice / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of Red Yeast Rice. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Red yeast rice contains lovastatin (possibly 2.4 mg per 600 mg of red yeast rice) and several other mevinic acid compounds, so these agents would be expected to interact in a similar manner to the interaction with lovastatin. <br><br>Consider using a non-interacting HMG-CoA reductase inhibitor (eg, pravastatin, pitavastatin) in patients receiving amiodarone. If these drugs are combined, limit the lovastatin dose to 40 mg daily and monitor for evidence of statin toxicities (eg, myalgia, liver function test elevations, rhabdomyolysis).</p> \n<p><b>Discussion</b> Although no studies or case reports have documented an interaction between amiodarone and lovastatin, numerous reports describe an interaction between amiodarone and simvastatin, a similar CYP3A4 metabolized statin. In a pharmacokinetic study conducted in 12 healthy volunteers, the AUC, maximum serum concentration, and elimination half-life of simvastatin (40 mg single dose) increased 73%, 100%, and 48%, respectively, after coadministration with amiodarone (400 mg/day x 3 days).<sup>1</sup> Several case reports describe patients taking simvastatin (40 to 80 mg daily) who developed severe simvastatin toxicities (eg, rhabdomyolysis, myopathy, myositis, acute renal failure) after initiation of amiodarone.<sup>2,3,4</sup> Other reports describe patients taking amiodarone who experienced simvastatin toxicities after initiation or dose escalation of simvastatin.<sup>5,6</sup> Two other case reports also describe simvastatin muscle toxicities with the use of these agents, but the presence of other interacting drugs in one case,<sup>7</sup> and the onset of symptoms not being temporally related to either drug initiation in the other,<sup>8</sup> make the role of this drug interaction in these cases less clear. <br><br>Lovastatin and amiodarone prescribing information both state that due to the risk of statin-related muscle toxicities, including rhabdomyolysis, the dose of lovastatin should be limited to 40 mg daily if combined with amiodarone.<sup>9,10</sup><br><br>The mechanism of this interaction is likely due to amiodarone-mediated inhibition of CYP3A4, an enzyme responsible for lovastatin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Becquemont L, Neuvonen M, Verstuyft C, et al. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. <i>Clin Pharmacol Ther</i>. 2007;81(5):679-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17301736\">[PubMed 17301736]</a></p>\n<p>2. Marot A, Morelle J, Chouinard VA, Jadoul M, Lambert M, Demoulin N. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. <i>Acta Clin Belg</i>. 2011;66(2):134-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21630612\">[PubMed 21630612]</a></p>\n<p>3. Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. <i>J Am Board Fam Med</i>. 2007;20(4):411-416. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17615423\">[PubMed 17615423]</a></p>\n<p>4. Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. <i>Ann Pharmacother</i>. 2004;38(6):978-981. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15069169\">[PubMed 15069169]</a></p>\n<p>5. Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. <i>Ann Pharmacother</i>. 2006;40(4):753-757. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16537817\">[PubMed 16537817]</a></p>\n<p>6. Wratchford P, Ponte CD. High-dose simvastatin and rhabdomyolysis. <i>Am J Health Syst Pharm</i>. 2003;60(7):698-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12701554\">[PubMed 12701554]</a></p>\n<p>7. Chouhan UM, Chakrabarti S, Millward LJ. Simvastatin interaction with clarithromycin and amiodarone causing myositis. Ann Pharmacother. 2005:39(10):1760-1761. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16159992\">[PubMed 16159992]</a></p>\n<p>8. Nagele H, Behrens S, Hashagen S, Azizi M. Rhabdomyolysis after addition of digitoxin to chronic simvastatin and amiodarone therapy. <i>Drug Metabol Drug Interact</i>. 2007;22(2-3):195-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17708069\">[PubMed 17708069]</a></p>\n<p>9. Mevacor (lovastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2014.</p>\n<p>10. Cordarone (amiodarone) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11041":"<p><b>Title</b> AtorvaSTATin / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of atorvastatin toxicities (eg, myalgia, liver function test elevations, rhabdomyolysis) if combined with amiodarone. Utilize lower starting and maintenance doses of atorvastatin in patients taking amiodarone.</p> \n<p><b>Discussion</b> Although no studies or case reports have documented an interaction between amiodarone and atorvastatin, numerous reports describe an interaction between amiodarone and simvastatin, a similar CYP3A4 metabolized statin. In a pharmacokinetic study conducted in 12 healthy volunteers, the AUC, maximum serum concentration, and elimination half-life of simvastatin (40 mg single dose) increased 73%, 100%, and 48%, respectively, after coadministration with amiodarone (400 mg/day x 3 days).<sup>1</sup> Several case reports describe patients taking simvastatin (40 to 80 mg daily) who developed severe simvastatin toxicities (eg, rhabdomyolysis, myopathy, myositis, acute renal failure) after initiation of amiodarone.<sup>2,3,4</sup> Other reports describe patients taking amiodarone who experienced simvastatin toxicities after initiation or dose escalation of simvastatin.<sup>5,6</sup> Two other case reports also describe simvastatin muscle toxicities with the use of these agents, but the presence of other interacting drugs in one case,<sup>7</sup> and the onset of symptoms not being temporally related to either drug initiation in the other,<sup>8</sup> make the role of this drug interaction in these cases less clear. <br><br>Amiodarone prescribing information states that due to the risk of statin-related muscle toxicities, including rhabdomyolysis, lower starting and maintenance doses of CYP3A4-metabolized statins (ie, atorvastatin) should be utilized.<sup>9</sup><br><br>The mechanism of this interaction is likely due to amiodarone-mediated inhibition of CYP3A4, an enzyme responsible for atorvastatin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Becquemont L, Neuvonen M, Verstuyft C, et al. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. <i>Clin Pharmacol Ther</i>. 2007;81(5):679-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17301736\">[PubMed 17301736]</a></p>\n<p>2. Marot A, Morelle J, Chouinard VA, Jadoul M, Lambert M, Demoulin N. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. <i>Acta Clin Belg</i>. 2011;66(2):134-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21630612\">[PubMed 21630612]</a></p>\n<p>3. Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. <i>J Am Board Fam Med</i>. 2007;20(4):411-416. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17615423\">[PubMed 17615423]</a></p>\n<p>4. Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. <i>Ann Pharmacother</i>. 2004;38(6):978-981. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15069169\">[PubMed 15069169]</a></p>\n<p>5. Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. <i>Ann Pharmacother</i>. 2006;40(4):753-757. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16537817\">[PubMed 16537817]</a></p>\n<p>6. Wratchford P, Ponte CD. High-dose simvastatin and rhabdomyolysis. <i>Am J Health Syst Pharm</i>. 2003;60(7):698-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12701554\">[PubMed 12701554]</a></p>\n<p>7. Chouhan UM, Chakrabarti S, Millward LJ. Simvastatin interaction with clarithromycin and amiodarone causing myositis. Ann Pharmacother. 2005:39(10):1760-1761. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16159992\">[PubMed 16159992]</a></p>\n<p>8. Nagele H, Behrens S, Hashagen S, Azizi M. Rhabdomyolysis after addition of digitoxin to chronic simvastatin and amiodarone therapy. <i>Drug Metabol Drug Interact</i>. 2007;22(2-3):195-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17708069\">[PubMed 17708069]</a></p>\n<p>9. Cordarone (amiodarone) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11042":"<p><b>Title</b> Rosuvastatin / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Amiodarone may enhance the hepatotoxic effect of Rosuvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A 73-year-old female patient being treated with gemfibrozil experienced a significant increase in LFTs (AST increased from 14 to 51 units/L and ALT increased from 13 to 91 units/L) after rosuvastatin was added to her regimen.<sup>1</sup> Gemfibrozil was discontinued and rosuvastatin was continued, and the AST and ALT decreased to 30 units/L and 58 units/L, respectively. Amiodarone 200 mg daily was then initiated post aortic valve replacement, and subsequently, the AST increased to 192 units/L and AST to 336 units/L two weeks later. Rosuvastatin was discontinued, and the AST and ALT decreased to 38 and 59 units/L, respectively, 2 months later.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown. It is possible that amiodarone inhibits enzymes that are partially responsible for rosuvastatin metabolism (ie, CYP2C9), or because both drugs have been associated with elevations in liver transaminases, their combined use may have additive effects on liver function. Additionally, the elevated transaminases seen in this case may not have been a result of a drug interaction at all, but rather hepatic congestion from severe aortic stenosis.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Merz T, Fuller SH. Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone. <i>Am J Health Syst Pharm</i>. 2007;64(17):1818-1821. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17724362\">[PubMed 17724362]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11043":"<p><b>Title</b> Iomeprol / Agents With Seizure Threshold Lowering Potential</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to the intrathecal administration of iohexol.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol and wait at least 24 hours after iomeprol administration before restarting such agents. In nonelective procedures in patients on these drugs, consider prophylactic use of anticonvulsants.</p>\n<div>\n <p><b>Agents With Seizure Threshold Lowering Potential Interacting Members</b> Aminophylline, Amisulpride, Amitriptyline, Amoxapine, Amphetamine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Benzphetamine, Blonanserin, Brexpiprazole, Bromperidol, BuPROPion, Caffeine, Cariprazine, ChlorproMAZINE, ClomiPRAMINE, Clothiapine, CloZAPine, Desipramine, Dexmethylphenidate, Dextroamphetamine, Diethylpropion, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Imipramine, Isocarboxazid, Kola Nut, Linezolid, Lisdexamfetamine, Lofepramine, Loxapine, Lurasidone, Melitracen [INT], Meperidine, Methamphetamine, Methotrimeprazine, Methylene Blue, Methylphenidate, Moclobemide, Molindone, Nortriptyline, OLANZapine, Paliperidone, Periciazine, Perphenazine, Phendimetrazine, Phenelzine, Phentermine, Pimozide, Pipamperone [INT], Pipotiazine, Procarbazine, Prochlorperazine, Promazine, Protriptyline, QUEtiapine, Rasagiline, RisperiDONE, Safinamide, Selegiline, Sulpiride, Syrian Rue, Tedizolid, Theophylline, Thioridazine, Thiothixene, TraMADol, Tranylcypromine, Trifluoperazine, Trimipramine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Iomeprol prescribing information states that drugs that lower the seizure threshold, especially phenothiazine derivatives and including those used for their antihistaminic or antinauseant properties, are not recommended for use with iomeprol.<sup>1</sup> Other drugs that may lower the seizure threshold include monoamine oxidase inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, or antipsychotic drugs. These medications should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours postprocedure.<sup>1</sup> In nonelective procedures in patients taking these drugs, consider prophylactic use of anticonvulsants.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Iomeron (iomeprol) [summary of product characteristics]. Sydney, New South Wales: Bracco Pty Ltd; February 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11044":"<p><b>Title</b> Iohexol / Agents With Seizure Threshold Lowering Potential</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to the intrathecal administration of iohexol.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol and wait at least 24 hours after iohexol administration before restarting such agents. In nonelective procedures in patients taking these drugs, consider prophylactic use of anticonvulsants.</p>\n<div>\n <p><b>Agents With Seizure Threshold Lowering Potential Interacting Members</b> Aminophylline, Amisulpride, Amitriptyline, Amoxapine, Amphetamine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Benzphetamine, Blonanserin, Brexpiprazole, Bromperidol, BuPROPion, Caffeine, Cariprazine, ChlorproMAZINE, ClomiPRAMINE, Clothiapine, CloZAPine, Desipramine, Dexmethylphenidate, Dextroamphetamine, Diethylpropion, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Imipramine, Isocarboxazid, Kola Nut, Linezolid, Lisdexamfetamine, Lofepramine, Loxapine, Lurasidone, Melitracen [INT], Meperidine, Methamphetamine, Methotrimeprazine, Methylene Blue, Methylphenidate, Moclobemide, Molindone, Nortriptyline, OLANZapine, Paliperidone, Periciazine, Perphenazine, Phendimetrazine, Phenelzine, Phentermine, Pimozide, Pipamperone [INT], Pipotiazine, Procarbazine, Prochlorperazine, Promazine, Protriptyline, QUEtiapine, Rasagiline, RisperiDONE, Safinamide, Selegiline, Sulpiride, Syrian Rue, Tedizolid, Theophylline, Thioridazine, Thiothixene, TraMADol, Tranylcypromine, Trifluoperazine, Trimipramine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Iohexol prescribing information states that drugs that lower the seizure threshold, especially phenothiazine derivatives and including those used for their antihistaminic or antinauseant properties, are not recommended for use with iohexol.<sup>1</sup> Other drugs that may lower the seizure threshold include monoamine oxidase inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, or antipsychotic drugs. These medications should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours postprocedure. In nonelective procedures in patients taking these drugs, consider prophylactic use of anticonvulsants.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Omnipaque (iohexol) [prescribing information]. Princeton, NJ: GE Healthcare Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11045":"<p><b>Title</b> Iopamidol / Agents With Seizure Threshold Lowering Potential</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to the intrathecal administration of iopamidol.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol and wait at least 24 hours after iopamidol administration before restarting such agents. In nonelective procedures in patients on these drugs, consider prophylactic use of anticonvulsants.</p>\n<div>\n <p><b>Agents With Seizure Threshold Lowering Potential Interacting Members</b> Aminophylline, Amisulpride, Amitriptyline, Amoxapine, Amphetamine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Benzphetamine, Blonanserin, Brexpiprazole, Bromperidol, BuPROPion, Caffeine, Cariprazine, ChlorproMAZINE, ClomiPRAMINE, Clothiapine, CloZAPine, Desipramine, Dexmethylphenidate, Dextroamphetamine, Diethylpropion, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Imipramine, Isocarboxazid, Kola Nut, Linezolid, Lisdexamfetamine, Lofepramine, Loxapine, Lurasidone, Melitracen [INT], Meperidine, Methamphetamine, Methotrimeprazine, Methylene Blue, Methylphenidate, Moclobemide, Molindone, Nortriptyline, OLANZapine, Paliperidone, Periciazine, Perphenazine, Phendimetrazine, Phenelzine, Phentermine, Pimozide, Pipamperone [INT], Pipotiazine, Procarbazine, Prochlorperazine, Promazine, Protriptyline, QUEtiapine, Rasagiline, RisperiDONE, Safinamide, Selegiline, Sulpiride, Syrian Rue, Tedizolid, Theophylline, Thioridazine, Thiothixene, TraMADol, Tranylcypromine, Trifluoperazine, Trimipramine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Iopamidol prescribing information states that drugs that lower the seizure threshold, especially phenothiazine derivatives and including those used for their antihistaminic or antinauseant properties, are not recommended for use with iopamidol.<sup>1</sup> Other drugs that may lower the seizure threshold include monoamine oxidase inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, or antipsychotic drugs. These medications should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours postprocedure.<sup>1</sup> In nonelective procedures in patients taking these drugs, consider prophylactic use of anticonvulsants.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Isovue-M (iopamidol) [prescribing information]. Princeton, NJ: Bracco Diagnostics Inc; January 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11046":"<p><b>Title</b> Radotinib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Radotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of radotinib with a strong CYP3A4 inhibitor should be avoided.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Radotinib labeling states that concurrent use with a strong CYP3A4 inhibitor should be avoided.<sup>1</sup> According to the labeling, the strong CYP3A4 inhibitor ketoconazole decreased radotinib metabolism by 80%. There is a concern that such a combination could result in increased radotinib concentrations and a greater risk for toxicities, including QT-interval prolongation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Supect (radotinib) capsules [KR prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201200121. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11047":"<p><b>Title</b> Radotinib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Radotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of radotinib with grapefruit juice should be avoided.</p> \n<p><b>Discussion</b> Radotinib labeling states that concurrent use with grapefruit juice should be avoided.<sup>1</sup> Both food and strong CYP3A4 inhibitors are capable of increasing radotinib concentrations, increasing the risk for toxicities, including QT-interval prolongation. Although grapefruit juice is only a moderate CYP3A4 inhibitor, it has widely varying effects and may also have a food-like impact.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Supect (radotinib) capsules [KR prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201200121. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11048":"<p><b>Title</b> Radotinib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Radotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible as the risk of radotinib treatment failure may be increased. If this combination must be used, monitor closely for evidence of reduced radotinib treatment response.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Radotinib labeling states that concurrent use with strong CYP3A4 inducers may increase the likelihood of radotinib treatment failure.<sup>1</sup> Radotinib appears to be primarily dependent on CYP3A4 for its metabolism, so it is expected that strong CYP3A4 inducers would increase radotinib metabolims, potentially resulting in substantially reduced radotinib exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Supect (radotinib) capsules [KR prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201200121. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11049":"<p><b>Title</b> Radotinib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Radotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible as the risk of radotinib treatment failure may be increased. If this combination must be used, monitor closely for evidence of reduced radotinib treatment response.</p> \n<p><b>Discussion</b> Radotinib labeling states that concurrent use with CYP3A4 inducers such as St John's wort (SJW) may increase the likelihood of radotinib treatment failure.<sup>1</sup> Radotinib appears to be primarily dependent on CYP3A4 for its metabolism, so it is expected that SJW would increase radotinib metabolims, potentially resulting in substantially reduced radotinib exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Supect (radotinib) capsules [KR prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201200121. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11060":"<p><b>Title</b> Phenylbutazone / Methylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Methylphenidate may increase the serum concentration of Phenylbutazone. Concentrations of the oxyphenbutazone metabolite may also be increased. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Phenylbutazone labeling states that concurrent use of methylphenidate and phenylbutazone may increase the serum concentration of the phenylbutazone metabolite oxyphenbutazone and prolongation of phenylbutazone half-life.<sup>1</sup> The magnitude and clinical significance of this apparent interaction are uncertain. The mechanism for this interaction is not known.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Phenylbutazone [summary of product characteristics]. Egham, Surrey, United Kingdom: Chemidex Pharma Limited; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11061":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Phenylbutazone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Phenylbutazone may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of phenylbutazone and other nonsteroidal anti-inflammatory agents is contraindicated.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The phenylbutazone labeling states that concurrent use of phenylbutazone with other nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 selective inhibitors and aspirin, is contraindicated due to an increased risk of adverse effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Phenylbutazone [summary of product characteristics]. Egham, Surrey, United Kingdom: Chemidex Pharma Limited; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11062":"<p><b>Title</b> MiFEPRIStone / Phenylbutazone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Phenylbutazone may diminish the therapeutic effect of MiFEPRIStone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Phenylbutazone should not be used for 8-12 days following mifepristone administration.</p> \n<p><b>Discussion</b> The manufacturer of phenylbutazone recommends avoiding concurrent use with mifepristone as the efficacy of mifepristone may be reduced with concurrent phenylbutazone, specifically recommending that phenylbutazone use should be avoided for 8-12 days following mifepristone administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Phenylbutazone [summary of product characteristics]. Egham, Surrey, United Kingdom: Chemidex Pharma Limited; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11063":"<p><b>Title</b> MiSOPROStol / Phenylbutazone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenylbutazone may enhance the neurotoxic effect of MiSOPROStol. Specifically, the combination may result in headache, dizziness, and transient diplopia. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients about a possible increased risk for adverse effects such as headache, dizziness, or diplopia with use of this combination, and monitor closely for the appearance of any such adverse effects.</p> \n<p><b>Discussion</b> The manufacturer of phenylbutazone recommends avoiding the concurrent use of misoprostol and phenylbutazone due to induction of adverse symptoms related to the central nervous systems such as dizziness, headache and transient diplopia.<sup>1</sup> Three published cases describe patients with spondyloarthritis who experienced adverse neurosensory symptoms following concurrent phenylbutazone and misoprostol.<sup>2,3</sup> When either agent was discontinued, the adverse events were no longer reported.<br><br>The mechanism for this interaction is not known.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Phenylbutazone [summary of product characteristics]. Egham, Surrey, United Kingdom: Chemidex Pharma Limited; October 2015.</p>\n<p>2. Chassagne P, Humez C, Gourmelen O, Moore N, Le Loet X, Deshayes P. Neurosensory adverse effects after combined phenylbutazone and misoprostol. <i>Br J Rheumatol</i>. 1991;30(5):392. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1913017\">[PubMed 1913017]</a></p>\n<p>3. Jacquemier JM, Lassoued S, Laroche M, Mazieres B. Neurosensory adverse effects after phenylbutazone and misoprostol combined treatment. <i>Lancet</i>. 1989;2(8674):1283. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2573801\">[PubMed 2573801]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11064":"<p><b>Title</b> Fosphenytoin-Phenytoin / Phenylbutazone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenylbutazone may increase the serum concentration of Fosphenytoin-Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of increased phenytoin concentrations, increased free phenytoin concentrations, and increased phenytoin effects with use of this combination.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Phenylbutazone labeling states that phenylbutazone may increase phenytoin concentrations (possibly both free and total) by displacing phenytoin from its protein binding sites and by inhibiting phenytoin metabolism.<sup>1</sup> The magnitude and clinical significance of this apparent interaction are uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Phenylbutazone [summary of product characteristics]. Egham, Surrey, United Kingdom: Chemidex Pharma Limited; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11065":"<p><b>Title</b> Zidovudine / Phenylbutazone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenylbutazone may enhance the adverse/toxic effect of Zidovudine. Specifically, the risk for bleeding or other hematologic toxicity may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor closely for evidence of bleeding with use of this combination.</p> \n<p><b>Discussion</b> Phenylbutazone labeling states that concurrent use of zidovudine may result in hematologic toxicity and that there have been reports of bleeding in patients with hemophilia who receive zidovudine together with ibuprofen, which, like phenylbutazone, is a nonsteroidal anti-inflammatory agent.<sup>1</sup> Published reports also describe bleeding problems associated with use of ibuprofen and zidovudine.<sup>2,3</sup><br><br>The specific mechanism for this possible interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Phenylbutazone [summary of product characteristics]. Egham, Surrey, United Kingdom: Chemidex Pharma Limited; October 2015. </p>\n<p>2. Ragni MV, Miller BJ, Whalen R, Ptachcinski R. Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. <i>Am J Hematol</i>. 1992;40(3):176-182. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1609771\">[PubMed 1609771]</a></p>\n<p>3. Pieper B, Smitherman HC Jr. Altered bleeding time associated with ibuprofen and zidovudine use. <i>Nurse Pract</i>. 1998;23(5):74-75, 80, 83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9614682\">[PubMed 9614682]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11066":"<p><b>Title</b> Phenylbutazone / Androgens</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Androgens may increase the serum concentration of Phenylbutazone. Specifically, concentrations of the oxyphenbutazone metabolite may be increased. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Androgens Interacting Members</b> Danazol, Fluoxymesterone, Mesterolone, MethylTESTOSTERone, Nandrolone, Oxandrolone, Oxymetholone, Testosterone</p>\n</div> \n<p><b>Discussion</b> Phenylbutazone labeling states that concurrent use of anabolic steroids and phenylbutazone may increase the serum concentration of the phenylbutazone metabolite oxyphenbutazone.<sup>1</sup> The magnitude and clinical significance of this apparent interaction are uncertain. The mechanism for this interaction is not known.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Phenylbutazone [summary of product characteristics]. Egham, Surrey, United Kingdom: Chemidex Pharma Limited; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11067":"<p><b>Title</b> QTc-Prolonging Agents (Highest Risk) / Promazine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Promazine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of promazine and drugs known to prolong the QTc interval.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Highest Risk) Interacting Members</b> Ajmaline, Amiodarone, Anagrelide, Arsenic Trioxide, Artemether, Asenapine, Astemizole, Bepridil, Cisapride, Citalopram, Deutetrabenazine, Disopyramide, Dofetilide, Domperidone, Dosulepin, Dronedarone, Eliglustat, FLUoxetine, Flupentixol, Halofantrine, Ibutilide, Iloperidone, Lopinavir, Lumefantrine, MiFEPRIStone, Nilotinib, Paliperidone, Pimavanserin, Pimozide, Pipamperone [INT], Procainamide, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ribociclib, Sotalol, Sparfloxacin, Sulpiride, Terfenadine, Tetrabenazine, Thioridazine, Toremifene, Vandetanib, Vemurafenib, Vernakalant, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> No published reports or studies describe the effect of promazine on the QTc interval. However, because promazine is an antipsychotic similar in structure to other agents known to prolong the QTc interval, promazine product labeling states that the use of promazine with other drugs known to prolong the QTc interval may increase the risk of ventricular<br>arrhythmias, including torsade de pointes, and should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Promazine [summary of product characteristics]. Leeds, Yorkshire, United Kingdom: Rosemont Pharmaceuticals Limited; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11068":"<p><b>Title</b> QTc-Prolonging Agents (Moderate Risk) / Promazine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Promazine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of promazine and drugs known to prolong the QTc interval.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Moderate Risk) Interacting Members</b> Azithromycin (Systemic), Bedaquiline, Benperidol, Ceritinib, Chloroquine, ChlorproMAZINE, Ciprofloxacin (Systemic), Clarithromycin, Clofazimine, CloZAPine, Crizotinib, Delamanid, Dolasetron, Droperidol, Efavirenz, Erythromycin (Systemic), Escitalopram, Flecainide, Gadobenate Dimeglumine, Gemifloxacin, Goserelin, Granisetron, Haloperidol, Inotuzumab Ozogamicin, Lenvatinib, Leuprolide, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lofexidine, Mequitazine, Methadone, Midostaurin, Moxifloxacin (Systemic), Ofloxacin (Systemic), OLANZapine, Ondansetron, Osimertinib, Panobinostat, PAZOPanib, Pentamidine (Systemic), Pilsicainide, Piperaquine, Primaquine, Probucol, Propafenone, RisperiDONE, Roxithromycin, Saquinavir, Sodium Stibogluconate, Telavancin, Telithromycin, Terlipressin</p>\n</div> \n<p><b>Discussion</b> No published reports or studies describe the effect of promazine on the QTc interval. However, because promazine is an antipsychotic similar in structure to other agents known to prolong the QTc interval, promazine product labeling states that the use of promazine with other drugs known to prolong the QTc interval may increase the risk of ventricular<br>arrhythmias, including torsade de pointes, and should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Promazine [summary of product characteristics]. Leeds, Yorkshire, United Kingdom: Rosemont Pharmaceuticals Limited; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11069":"<p><b>Title</b> Myelosuppressive Agents / Promazine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Promazine may enhance the myelosuppressive effect of Myelosuppressive Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased risk of myelosuppression (eg, neutropenia, agranulocytosis) if promazine is combined with other myelosuppressive agents.</p>\n<div>\n <p><b>Myelosuppressive Agents Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Aldesleukin, Alemtuzumab, Altretamine, Amsacrine, Arsenic Trioxide, AzaCITIDine, Belinostat, Belotecan, Bendamustine, Bevacizumab, Bexarotene (Systemic), Blinatumomab, Bortezomib, Bosutinib, Busulfan, Cabazitaxel, Capecitabine, CarBAMazepine, Carbimazole, CARBOplatin, Carfilzomib, Carmustine, Chlorambucil, Chloramphenicol (Ophthalmic), Chloramphenicol (Systemic), CISplatin, Cladribine, Clofarabine, Copanlisib, Cyclophosphamide, Cytarabine (Conventional), Dacarbazine, DACTINomycin, Daratumumab, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Decitabine, Dexrazoxane, Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Edetate CALCIUM Disodium, EpiRUBicin, EriBULin, Etoposide, Etoposide Phosphate, Everolimus, Floxuridine, Flucytosine, Fludarabine, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Inotuzumab Ozogamicin, Interferon Alfa-2a, Interferon Alfa-2b, Interferon Alfa-n3, Interferon Alfacon-1, Irinotecan (Conventional), Irinotecan (Liposomal), Ixabepilone, Ixazomib, Lenalidomide, Linezolid, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, MethIMAzole, Methotrexate, Midostaurin, MitoMYcin (Systemic), MitoXANTRONE, Nelarabine, Nilotinib, Niraparib, Obinutuzumab, Olaparib, Olaratumab, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Peginterferon Alfa-2a, Peginterferon Alfa-2b, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PONATinib, Procarbazine, Propylthiouracil, Radium Ra 223 Dichloride, Radotinib, Raltitrexed, Ribociclib, RiTUXimab, RomiDEPsin, Rucaparib, Ruxolitinib, Sirolimus, SORAfenib, Streptozocin, Tacrolimus (Systemic), Tedizolid, Tegafur, Temozolomide, Temsirolimus, Teniposide, Thalidomide, Thioguanine, Thiotepa, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Trifluridine and Tipiracil, Venetoclax, VinBLAStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine, Vorinostat, Zidovudine, Ziv-Aflibercept (Systemic)</p>\n</div> \n<p><b>Discussion</b> Numerous reports have described patients who experienced severe neutropenia and agranulocytosis with the use of promazine.<sup>1,2,3,4,5,6,7,8,9,10,11,12</sup> Promazine product labeling states that use of promazine with other drugs associated with myelosuppression may increase the risk of these toxicities.<sup>13</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bennett NM. Drug-induced agranulocytosis and septicaemia. <i>Med J Aust</i>. 1963;2:575-577. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14052118\">[PubMed 14052118]</a></p>\n<p>2. Zweifler AJ. Agranulocytosis and jaundice during therapy with meprobamate and promazine. <i>N Engl J Med</i>. 1960;262:1229-1231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13847966\">[PubMed 13847966]</a></p>\n<p>3. Holmes JR, Barg P. Fatal agranulocytosis during promazine therapy. <i>Can Med Assoc J</i>. 1959;81:384. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14402787\">[PubMed 14402787]</a></p>\n<p>4. Michaelson AK. Severe leukemoid reaction after promazine-induced agranulocytosis. <i>J Fla Med Assoc</i>. 1959;45(12):1418-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13654688\">[PubMed 13654688]</a></p>\n<p>5. Kreisle JE. Agranulocytosis during promazine (sparine) therapy: report of a case. <i>Tex State J Med</i>. 1959;55(4):297-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13647404\">[PubMed 13647404]</a></p>\n<p>6. Glaser GL, Adams DA. Agranulocytosis associated with promazine administration: report of three cases. <i>Ann Intern Med</i>. 1958;48(2):372-379. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13509542\">[PubMed 13509542]</a></p>\n<p>7. Earle BV. Fatal agranulocytosis due to promazine hydrochloride. <i>Lancet</i>. 1957;273(7002):925-926. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13482248\">[PubMed 13482248]</a></p>\n<p>8. Reinhart MJ, Silverstein BS, Cross TN. A case of agranulocytosis following sparine administration. <i>Am J Psychiatry</i>. 1957;114(5):462-463. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13470123\">[PubMed 13470123]</a></p>\n<p>9. Cook IA, Melrose AG, Roy JR. Agranulocytosis with recovery during promazine therapy. <i>Br Med J</i>. 1957;2(5039):276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13446460\">[PubMed 13446460]</a></p>\n<p>10. Williams RO, Johnson HI Jr, Blankinship R. Agranulocytosis occurring during promazine therapy; report of a case. <i>Va Med Mon (1918)</i>. 1957;84(8):406-407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13456354\">[PubMed 13456354]</a></p>\n<p>11. Chirico AM, Carfagno S, Lytel F. Agranulocytosis after promazine therapy. <i>N Engl J Med</i>. 1957;256(19):899-900. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13451962\">[PubMed 13451962]</a></p>\n<p>12. Solomon JD, Woodward DJ. Fatal agranulocytosis occurring during promazine (sparine) therapy. <i>J Am Med Assoc</i>. 1956;162(14):1308-1309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13366748\">[PubMed 13366748]</a></p>\n<p>13. Promazine [summary of product characteristics]. Leeds, Yorkshire, United Kingdom: Rosemont Pharmaceuticals Limited; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11070":"<p><b>Title</b> Promazine / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Loop Diuretics may enhance the QTc-prolonging effect of Promazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of promazine and loop diuretics.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> No published reports or studies describe the effect of promazine on the QTc interval. However, because promazine is an antipsychotic similar in structure to other agents known to prolong the QTc interval, promazine product labeling states that the use of promazine with diuretics known to cause hypokalemia may increase the risk of ventricular<br>arrhythmias, including torsade de pointes, and should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Promazine [summary of product characteristics]. Leeds, Yorkshire, United Kingdom: Rosemont Pharmaceuticals Limited; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11071":"<p><b>Title</b> Promazine / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Promazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of promazine and thiazide and thiazide-like diuretics.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> No published reports or studies describe the effect of promazine on the QTc interval. However, because promazine is an antipsychotic similar in structure to other agents known to prolong the QTc interval, promazine product labeling states that the use of promazine with diuretics known to cause hypokalemia may increase the risk of ventricular<br>arrhythmias, including torsade de pointes, and should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Promazine [summary of product characteristics]. Leeds, Yorkshire, United Kingdom: Rosemont Pharmaceuticals Limited; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11072":"<p><b>Title</b> Rilmenidine / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Rilmenidine. Specifically, alcohol increased the CNS depressant effect of rilmenidine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Alcohol consumption is not recommended during treatment with rilmenidine.</p> \n<p><b>Discussion</b> Rilmenidine labeling states that consumption of alcohol is not recommended while being treated with rilmenidine.<sup>1,2</sup> Specific data concerning this combination are not provided.<br><br>The mechanism is likely possible additive or synergistic CNS depression with concurrent use.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hyperium (rilmenidine) [prescribing information]. Rio de Janeiro, Brazil: Laboratorios Servier de Brasil Ltda; November 2016.</p>\n<p>2. Hyperium (rilmenidine) [summary of product characteristics]. Cedex, France: Les Laboratoires Servier; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11073":"<p><b>Title</b> Digoxin / Manidipine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Manidipine may increase the serum concentration of Digoxin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Manidipine product labeling states that concomitant use of manidipine and digoxin may result in increased digoxin concentrations and toxicities.<sup>1</sup> Although manidipine has not been evaluated in a clinical study with digoxin, this warning appears to be based on the fact that a similar dihydropyridine calcium channel blocker, nifedipine, has been shown to increase digoxin concentrations.<sup>2,3</sup> It should be noted, however, that this may not be a class effect because other dihydropyridine calcium channel blockers do not appear to affect digoxin exposure (eg, amlodipine, felodipine, isradipine, nicardipine).<sup>4,5,6,7,8</sup><br><br>The mechanism of this potential interaction is unknown, but inhibition of P-glycoprotein by manidipine may contribute.<sup>9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Manivasc (manidipine) [summary of product characteristics]. Sao Paulo, Brazil: Chiesi Farmaceutici Ltda; April 2013. </p>\n<p>2. Belz GG, Aust PE, Munkes R. Digoxin plasma concentrations and nifedipine. <i>Lancet</i>. 1981;1(8224):844-845. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6111709\">[PubMed 6111709]</a></p>\n<p>3. Schwartz JB, Migliore PJ. Effect of nifedipine on serum digoxin concentration and renal digoxin clearance. <i>Clin Pharmacol Ther</i>. 1984;36(1):19-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6734045\">[PubMed 6734045]</a></p>\n<p>4. Snyder BD, Rowland A, Polasek TM, Miners JO, Doogue MP. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. <i>Eur J Clin Pharmacol</i>. 2014;70(9):1115-1122. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25028073\">[PubMed 25028073]</a></p>\n<p>5. Kirch W, Laskowski M, Ohnhaus EE, Aberg J. Effects of felodipine on plasma digoxin levels and haemodynamics in patients with heart failure. <i>J Intern Med</i>. 1989;225(4):237-239. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2656902\">[PubMed 2656902]</a></p>\n<p>6. Schwartz JB. Effects of amlodipine on steady-state digoxin concentrations and renal digoxin clearance. <i>J Cardiovasc Pharmacol</i>. 1988;12(1):1-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2459525\">[PubMed 2459525]</a></p>\n<p>7. Rodin SM, Johnson BF, Wilson J, Ritchie P, Johnson J. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. <i>Clin Pharmacol Ther</i>. 1988;43(6):668-672. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2967742\">[PubMed 2967742]</a></p>\n<p>8. Debruyne D, Commeau P, Grollier G, Huret B, Scanu P, Moulin M. Nicardipine does not significantly affect serum digoxin concentrations at the steady state of patients with congestive heart failure. <i>Int J Clin Pharmacol Res</i>. 1989;9(1):15-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2707921\">[PubMed 2707921]</a></p>\n<p>9. Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. <i>Pharm Res</i>. 2000;17(10):1189-1197. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11145223\">[PubMed 11145223]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11074":"<p><b>Title</b> Manidipine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Manidipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding concomitant use of manidipine and strong CYP3A4 inhibitors. If combined, monitor closely for increased manidipine effects and toxicities. Manidipine dose reductions may be required.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> No studies have evaluated the effects of strong CYP3A4 inhibitors on manidipine pharmacokinetics. However, in a pharmacokinetic study of 7 healthy volunteers, coadministration of racemic manidipine (40 mg single dose) with the moderate CYP3A4 inhibitor grapefruit juice (250 mL) increased the S-manidipine AUC and maximum serum concentration (Cmax) 2.4-fold and increased the R-manidipine AUC and Cmax 3.0-fold and 3.4-fold, respectively.<sup>1</sup><br><br>Manidipine product labeling in some countries suggests avoiding the combination of manidipine and strong CYP3A4 inhibitors.<sup>2</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4, an enzyme responsible for manidipine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Uno T, Ohkubo T, Motomura S, Sugawara K. Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects. <i>Br J Clin Pharmacol</i>. 2006;61(5):533-537. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16669846\">[PubMed 16669846]</a></p>\n<p>2. Manivasc (manidipine) [summary of product characteristics]. Sao Paulo, Brazil: Chiesi Farmaceutici Ltda; April 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11075":"<p><b>Title</b> Manidipine / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Manidipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding concomitant use of manidipine and strong CYP3A4 inducers. If combined, monitor closely for decreased manidipine effects and loss of efficacy. Increased manidipine doses may be required.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> No studies have evaluated the effects of strong CYP3A4 inducers on manidipine pharmacokinetics. However, like other dihydropyridine calcium channel blockers, CYP3A4 is responsible for the metabolism of manidipine and use with strong CYP3A4 inducers is expected to result in reduced manidipine concentrations and effects.<sup>1</sup> Manidipine product labeling in some countries suggests avoiding the combination of manidipine and strong CYP3A4 inducers.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Manivasc (manidipine) [summary of product characteristics]. Sao Paulo, Brazil: Chiesi Farmaceutici Ltda; April 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11076":"<p><b>Title</b> Manidipine / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased manidipine effects and toxicities if combined with a moderate CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 7 healthy volunteers, coadministration of racemic manidipine (40 mg single dose) and the moderate CYP3A4 inhibitor grapefruit juice (250 mL) increased the S-manidipine AUC and maximum serum concentration (Cmax) 2.4-fold and increased the R-manidipine AUC and Cmax 3.0-fold and 3.4-fold, respectively.<sup>1</sup><br><br>The mechanism of this interaction is likely due to grapefruit juice-mediated inhibition of intestinal CYP3A4, an enzyme responsible for manidipine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Uno T, Ohkubo T, Motomura S, Sugawara K. Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects. <i>Br J Clin Pharmacol</i>. 2006;61(5):533-537. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16669846\">[PubMed 16669846]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11077":"<p><b>Title</b> Sodium Oxybate / Rilmenidine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rilmenidine may enhance the CNS depressant effect of Sodium Oxybate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of rilmenidine and sodium oxybate is not recommended.</p> \n<p><b>Discussion</b> Rilmenidine labeling states that concurrent use with sodium oxybate is not recommended while being treated with rilmenidine.<sup>1,2</sup> Specific data concerning this combination are not provided.<br><br>The mechanism is likely possible additive or synergistic CNS depression with concurrent use.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hyperium (rilmenidine) [prescribing information]. Rio de Janeiro, Brazil: Laboratorios Servier de Brasil Ltda; November 2016.</p>\n<p>2. Hyperium (rilmenidine) [summary of product characteristics]. Cedex, France: Les Laboratoires Servier; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11078":"<p><b>Title</b> Rilmenidine / Alpha1-Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alpha1-Blockers may enhance the hypotensive effect of Rilmenidine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of hypotension with use of this combination. Inform patients about the possible increased risk for hypotension, and particularly for orthostatic hypotension. This warning specifically includes both specific and non-specific alpha-blockers as well as antihypertensive and urological use of alpha-blockers. The risk is likely lower with use of prostate-specific alpha-blockers.</p>\n<div>\n <p><b>Alpha1-Blockers Interacting Members</b> Alfuzosin, Doxazosin, Indoramin, Moxisylyte, Naftopidil, Nicergoline, Phenoxybenzamine, Phentolamine, Prazosin, Silodosin, Tamsulosin, Terazosin</p>\n</div> \n<p><b>Discussion</b> Rilmenidine labeling states that concurrent use with alpha-blockers may increase the risk for hypotension and orthostatic hypotension.<sup>1,2</sup> Specific data concerning this combination are not provided.<br><br>The mechanism for this potential interaction is likely additive or synergistic vasodilation or hypotension with use of the combination.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hyperium (rilmenidine) [prescribing information]. Rio de Janeiro, Brazil: Laboratorios Servier de Brasil Ltda; November 2016.</p>\n<p>2. Hyperium (rilmenidine) [summary of product characteristics]. Cedex, France: Les Laboratoires Servier; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11079":"<p><b>Title</b> Rilmenidine / Vasodilators (Organic Nitrates)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Rilmenidine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of hypotension with use of this combination. Inform patients about the possible increased risk for hypotension, and particularly for orthostatic hypotension.</p>\n<div>\n <p><b>Vasodilators (Organic Nitrates) Interacting Members</b> Isosorbide Dinitrate, Isosorbide Mononitrate, Nicorandil, Nitroglycerin</p>\n</div> \n<p><b>Discussion</b> Rilmenidine labeling states that concurrent use with nitrates may increase the risk for hypotension and orthostatic hypotension.<sup>1,2</sup> Specific data concerning this combination are not provided.<br><br>The mechanism for this potential interaction is likely additive or synergistic vasodilation or hypotension with use of the combination.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hyperium (rilmenidine) [prescribing information]. Rio de Janeiro, Brazil: Laboratorios Servier de Brasil Ltda; November 2016.</p>\n<p>2. Hyperium (rilmenidine) [summary of product characteristics]. Cedex, France: Les Laboratoires Servier; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11080":"<p><b>Title</b> Alcohol (Ethyl) / Sulfamethoxazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Sulfamethoxazole may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, this combination may result in a disulfiram-like reaction. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A published case report describes both a 31-year-old and a 39-year-old who were each being treated with sulfamethoxazole/trimethoprim (SMZ/TMP) (for 3 days in both cases) and developed flushing, dyspnea, palpitations, headache, and nausea within 10-20 minutes after consumption of two or three 12-ounce beers.<sup>1</sup> Symptoms gradually resolved over the next several hours. One patient had a recurrence of symptoms the following day after consuming 6 ounces of beer, while the other patient reported consuming beer the day prior to this episode (ie, after 2 days of SMZ/TMP) without any such symptoms.<br><br>The specific mechanism for this potential interaction is uncertain, but structural similarities between sulfamethoxazole and sulfonylureas suggest the mechanism may be similar to the manner by which sulfonylureas cause a disulfiram-type reaction with alcohol.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Heelon MW, White M. Disulfiram-cotrimoxazole reaction. <i>Pharmacotherapy</i>. 1998;18(4):869-870. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9692665\">[PubMed 9692665]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11081":"<p><b>Title</b> Dabigatran Etexilate / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Dabigatran Etexilate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Closely monitor patients for decreased concentrations/effects of dabigatran with concurrent carbamazepine. Dabigatran labeling recommends avoiding concurrent use of dabigatran with strong p-glycoprotein inducers whenever possible, and although US labeling does not list carbamazepine as an example of a strong p-glycoprotein inducer, at least some international labeling does. Available evidence is not conclusive on whether carbamazepine is a strong p-glycoprotein inducer.</p> \n<p><b>Discussion</b> Dabigatran AUC and maximum serum concentration (Cmax) were an average of 66% and 67% lower, respectively, when a single dose of dabigatran was given after 7 days of the p-glycoprotein inducer rifampin (600 mg/day).<sup>1</sup> When tested 7 days after rifampin discontinuation, dabigatran concentrations were similar to no-rifampin concentrations.<br><br>Dabigatran levels were undetectable 10 hours after a dose of dabigatran with concomitant phenytoin usage in a published case report of a 45 year old African American male taking dabigatran 150 mg twice daily and phenytoin 100 mg three times daily.<sup>2</sup> Dabigatran levels were similarly subtherapeutic in a patient receiving concomitant phenytoin and phenobarbital, two known P-glycoprotein inducers, in a study assessing trough concentrations of dabigatran with respect to variable renal function measurements.<sup>3</sup> This patient’s trough dabigatran level was 9 mcg/L, which was more than 3 standard deviations below the mean dose-corrected trough concentrations of the cohort (70 mcg/L) and well below previously reported therapeutic trough concentrations of 30-130 mcg/L.<br><br>Based on these data, the U.S. prescribing information and Canadian product monograph for dabigatran recommend avoiding use of dabigatran with p-glycoprotein inducers.<sup>1,4</sup> Whether carbamazepine is a strong p-glycoprotein inducer is unclear. Studies with the p-glycoprotein substrate fexofenadine do support p-glycoprotein induction, but studies with the substrates digoxin and talinolol show no significant p-glycoprotein induction.<sup>5,6,7,8</sup> The Canadian labeling does list carbamazepine as an example of a potent p-glycoprotein inducer, but US labeling does not.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pradaxa (dabigatran etexilate) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; October 2010.</p>\n<p>2. Wiggins BS, Northup A, Johnson D, Senfield J. Reduced anticoagulant effect of dabigatran in a patient receiving concomitant phenytoin. <i>Pharmacotherapy</i>. 2016;36(2):e5-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26846610\">[PubMed 26846610]</a></p>\n<p>3. Chin PK, Wright DF, Zhang M, et al. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. <i>Drugs R D</i>. 2014;14(2):113-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24797400\">[PubMed 24797400]</a></p>\n<p>4. Pradax (dabigatran etexilate) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd.; August 2016.</p>\n<p>5. Akamine Y, Miura M, Yasui-Furukori N, Kojima M, Uno T. Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. <i>Br J Clin Pharmacol</i>. 2012;73(3):478-481. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21950458\">[PubMed 21950458]</a></p>\n<p>6. Yamada S, Yasui-Furukori N, Akamine Y, Kaneko S, Uno T. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. <i>Ther Drug Monit</i>. 2009;31(6):764-768. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19855315\">[PubMed 19855315]</a></p>\n<p>7. Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandstrom R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. <i>Clin Pharmacol Ther</i>. 2008;84(1):52-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17971810\">[PubMed 17971810]</a></p>\n<p>8. Giessmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. <i>Clin Pharmacol Ther</i>. 2004;76(3):192-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15371980\">[PubMed 15371980]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11082":"<p><b>Title</b> Etelcalcetide / Cinacalcet</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cinacalcet may enhance the hypocalcemic effect of Etelcalcetide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use. When changing from cinacalcet to etelcalcetide, discontinue cinacalcet for at least 7 days prior to starting etelcalcetide, and start etelcalcetide at a dose of 5 mg. Be sure corrected serum calcium concentration is at least at the lower limit of normal before starting therapy.</p> \n<p><b>Discussion</b> The etelcalcetide labeling states that concurrent use with any other calcimimetic could result in severe hypocalcemia.<sup>1</sup> When changing from cinacalcet to etelcalcetide, discontinue cinacalcet for at least 7 days prior to starting etelcalcetide, and start etelcalcetide at a dose of 5 mg. Be sure corrected serum calcium concentration is at the lower limit of normal or higher before starting therapy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Parsabiv (etelcalcetide) [prescribing information]. Thousand Oaks, CA: KAI Pharmaceuticals, Inc.; February 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11083":"<p><b>Title</b> Hydroxychloroquine / Tamoxifen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tamoxifen may enhance the adverse/toxic effect of Hydroxychloroquine. Specifically, concomitant use of tamoxifen and hydroxychloroquine may increase the risk of retinal toxicity. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients annually for increased risk of retinal toxicity if hydroxychloroquine is combined with tamoxifen.</p> \n<p><b>Discussion</b> In a large study of hydroxychloroquine-treated patients, concomitant use of tamoxifen was associated with an increased risk for retinal toxicity (OR 4.59; 95% CI [2.05 to 10.27]).<sup>1</sup> The American Academy of Ophthalmology revised recommendations and hydroxychloroquine product labeling recommend careful dosing and regular annual screening (as opposed to screening every 5 years) for patients taking tamoxifen and hydroxychloroquine concomitantly.<sup>2,3</sup><br><br>The mechanism of the interaction has not been established, but tamoxifen alone is a known retinal toxin and adverse synergism with hydroxychloroquine may play a role.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. <i>JAMA Ophthalmol</i>. 2014;132(12):1453-1460. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25275721\">[PubMed 25275721]</a></p>\n<p>2. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). <i>Ophthalmology</i>. 2016;123(6):1386-1394. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26992838\">[PubMed 26992838]</a></p>\n<p>3. Plaquenil (hydroxychloroquine) [prescribing information]. St. Michael, Barbados: Concordia Pharmaceuticals Inc; January 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11089":"<p><b>Title</b> Sertraline / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Sertraline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of sertraline if combined with a strong CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a retrospective analysis of patients taking sertraline, those who received sertraline monotherapy (54 patients) had a 3.12-fold higher concentration-to-daily dose ratio compared with patients who received sertraline with either carbamazepine or phenytoin (9 patients).<sup>1</sup> A case report describes 2 patients who, despite increasing sertraline doses up to 300 mg per day, experienced undetectable sertraline serum concentrations and a lack of sertraline efficacy when added to stable carbamazepine therapy.<sup>2</sup> Another case report describes a 34-year male patient taking sertraline 200 mg daily who experienced symptoms of sertraline withdrawal (eg, increasing anxiety, lethargy, dizziness, insomnia) 7 days after initiation of rifampin 300 mg twice daily.<sup>3</sup> Sertraline levels taken during rifampin therapy were 67% lower than sertraline levels drawn 7 days after rifampin discontinuation.<sup>3</sup><br><br>The mechanism of this potential interaction is likely due to induction of CYP3A4-mediated sertraline metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pihlsgard M, Eliasson E. Significant reduction of sertraline plasma levels by carbamazepine and phenytoin. <i>Eur J Clin Pharmacol</i>. 2002:57(12):915-916. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936714\">[PubMed 11936714]</a></p>\n<p>2. Khan A, Shad MU, Preskorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine. <i>J Clin Psychiatry</i>. 2000:61(7):526-527. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10937612\">[PubMed 10937612]</a></p>\n<p>3. Markowitz JS, DeVane CL. Rifampin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline. <i>J Clin Psychopharmacol</i>. 2000;20(1):109-110. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10653222\">[PubMed 10653222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11090":"<p><b>Title</b> Midazolam / Brodalumab</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Brodalumab may increase the serum concentration of Midazolam. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the brodalumab prescribing information, brodalumab (210 mg single dose given on day 1) increased midazolam (single dose given on day 7) exposure 24%.<sup>1</sup><br><br>The mechanism of this interaction is unknown. The formation of CYP450 enzymes can be altered by increased levels of certain cytokines that are often present during chronic inflammation. Typically, treatment with immunomodulators reduces cytokine levels, improves CYP450 function, and reduces serum concentrations of CYP450 substrates. In this case, the opposite effect appears to have occurred, with brodalumab treatment resulting in increased concentrations of the CYP3A4 substrate midazolam.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Siliq (brodalumab) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; February 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11091":"<p><b>Title</b> Blood Glucose Lowering Agents / Prothionamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Prothionamide may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for hypoglycemia if prothionamide is combined with blood glucose lowering agents. Blood glucose should be determined prior to and periodically throughout concomitant therapy.</p>\n<div>\n <p><b>Blood Glucose Lowering Agents Interacting Members</b> Acarbose, Albiglutide, Alogliptin, Anagliptin, Bromocriptine, Canagliflozin, Chloroquine, ChlorproPAMIDE, Dapagliflozin, Disopyramide, Dulaglutide, Empagliflozin, Ertugliflozin, Evogliptin, Exenatide, Gemigliptin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Hydroxychloroquine, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Ipragliflozin, Lanreotide, Linagliptin, Liraglutide, Lixisenatide, Lobeglitazone, Mecasermin, MetFORMIN, MiFEPRIStone, Miglitol, Mitiglinide, Nateglinide, Octreotide, Pasireotide, Pentamidine (Systemic), Perhexiline, Pioglitazone, Pramlintide, QuiNINE, Repaglinide, Rosiglitazone, SAXagliptin, Semaglutide, SITagliptin, Somatostatin Acetate, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, SUNItinib, Teneligliptin, TOLAZamide, TOLBUTamide, Vildagliptin, Voglibose</p>\n</div> \n<p><b>Discussion</b> Prothionamide product labeling warns that because prothionamide treatment has been associated with hypoglycemia, use with other agents that lower blood glucose could result in an increased risk of hypoglycemia.<sup>1,2</sup> Increased blood glucose monitoring during concomitant therapy is recommended.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prothionamide [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199302671. Accessed November 23, 2016.</p>\n<p>2. Protionamide [WHO Public Assessment Report part 4]. Available at: http://apps.who.int/prequal/whopar/whoparproducts/TB239part4v02.pdf. Accessed February 2, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11092":"<p><b>Title</b> Prothionamide / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may enhance the hepatotoxic effect of Prothionamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of prothionamide and rifampin if possible. If combined use is considered necessary, monitor patients closely for signs and symptoms of hepatotoxicity (eg, jaundice, elevations in liver function tests).</p> \n<p><b>Discussion</b> In 2 studies of patients treated for leprosy (N = 163 to 204), acute hepatitis occurred in 13% to 16.5% of patients who received a three drug regimen consisting of prothionamide, rifampin and dapsone, while no cases of hepatitis occurred among patients who received a two drug regimen consisting of rifampin and dapsone.<sup>1,2</sup> In all cases, hepatitis resolved with discontinuation of rifampin and prothionamide, and subsequent treatment with rifampin alone resulted in no recurrence of liver injury.<sup>1,2</sup> In another study of leprosy patients (N = 100), the incidence of jaundice was higher among patients who received prothionamide, rifampin, and dapsone compared with patients who received clofazimine, rifampin, and dapsone (20% vs 4%).<sup>3</sup> An additional study reported the incidence of hepatotoxicity to be 22% to 56% among patients treated with multidrug regimens containing prothionamide and rifampin, with some cases being fatal.<sup>4</sup><br><br>Prothionamide product labeling states that the coadministration of prothionamide and rifampin has resulted in a high rate of hepatotoxicity, some fatal, and concomitant use should be avoided if possible. If the benefit of coadministration appears to outweigh the risks, then monitor patients closely for signs and symptoms of hepatotoxicity during combined use.<sup>5,6</sup><br><br>The mechanism of this interaction has not been fully investigated, but both rifampin and prothionamide have been associated with hepatotoxicity so their combined use may have additive adverse effects on the liver. Additionally, it has been proposed that rifampin may induce the metabolism of prothionamide and increase the production of hepatotoxic metabolites.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cartel JL, Millan J, Guelpa-Lauras CC, Grosset JH. Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. <i>Int J Lepr Other Mycobact Dis</i>. 1983;51(4):461-465. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6686970\">[PubMed 6686970]</a></p>\n<p>2. Cartel JL, Naudillon Y, Artus JC, Grosset JH. Hepatotoxicity of the daily combination of 5 mg/kg prothionamide and 10 mg/kg rifampin. <i>Int J Lepr Other Mycobact Dis</i>. 1985;53(1):15-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3998559\">[PubMed 3998559]</a></p>\n<p>3. Kar HK, Balakrishnan S, Vasantha Kumar G, Sirumban P, Roy RG. Hepatitis and multi-drug therapy in leprosy with special reference to prothionamide. <i>Indian J Lepr</i>. 1985;57(1):78-89. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3839828\">[PubMed 3839828]</a></p>\n<p>4. Ji BH, Chen JK, Wang CM, Xia GA. Hepatotoxicity of combined therapy with rifampicin and daily prothionamide for leprosy. <i>Lepr Rev</i>. 1984;55(3):283-289. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6492989\">[PubMed 6492989]</a></p>\n<p>5. Prothionamide [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199302671. Accessed November 23, 2016.</p>\n<p>6. Protionamide [WHO Public Assessment Report part 4]. Available at: http://apps.who.int/prequal/whopar/whoparproducts/TB239part4v02.pdf. Accessed February 2, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11093":"<p><b>Title</b> CycloSERINE / Prothionamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Prothionamide may enhance the adverse/toxic effect of CycloSERINE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for symptoms of pellagra-like encephalopathy (eg, confusion, weakness, ataxia, depression) if prothionamide is combined with cycloserine. Supplementation with pyridoxine and/or niacin may help improve symptoms.</p> \n<p><b>Discussion</b> Prothionamide product labeling states that because the combination of ethionamide and cycloserine has been reported to precipitate a pellagra-like encephalopathy, patients should be monitored closely for symptoms of encephalopathy if prothionamide and cycloserine are combined.<sup>1,2,3</sup><br><br>The mechanism of this potential interaction is unknown, but disturbances in pyridoxine or niacin metabolism may play a role.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prothionamide [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199302671. Accessed November 23, 2016.</p>\n<p>2. Protionamide [WHO Public Assessment Report part 4]. Available at: http://apps.who.int/prequal/whopar/whoparproducts/TB239part4v02.pdf. Accessed February 2, 2016.</p>\n<p>3. Swash M, Roberts AH, Murnaghan DJ. Reversible pellagra-like encephalopathy with ethionamide and cycloserine. <i>Tubercle</i>. 1972;53(2):132-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4261138\">[PubMed 4261138]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11094":"<p><b>Title</b> Prothionamide / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Prothionamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of alcohol and prothionamide.</p> \n<p><b>Discussion</b> Prothionamide product labeling states that because excessive ethanol use during ethionamide therapy has been reported to precipitate a psychotic reaction, the use of prothionamide and alcohol should be avoided.<sup>1,2</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prothionamide [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199302671. Accessed November 23, 2016.</p>\n<p>2. Protionamide [WHO Public Assessment Report part 4]. Available at: http://apps.who.int/prequal/whopar/whoparproducts/TB239part4v02.pdf. Accessed February 2, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11095":"<p><b>Title</b> Prothionamide / Isoniazid</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Isoniazid may increase the serum concentration of Prothionamide. Prothionamide may increase the serum concentration of Isoniazid. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider a prothionamide dose reduction and do not exceed 500 mg per day if combined with isoniazid. Monitor patients for increased prothionamide effects/toxicities. Additionally, monitor for increased isoniazid effects/toxicities (eg, peripheral neuropathy, encephalopathy, hepatotoxicity) and ensure pyridoxine supplementation is provided if these drugs are combined.</p> \n<p><b>Discussion</b> Prothionamide product labeling states that isoniazid may increase prothionamide concentrations.<sup>1,2</sup> If these agents are combined, reduced prothionamide doses may be required, and the prothionamide dose should not exceed 500 mg per day.<sup>2</sup><br><br>Additionally, prothionamide product labeling states that because the combination of ethionamide and isoniazid has resulted in increased isoniazid concentrations, if prothionamide and isoniazid are combined, patients should be monitored for increased isoniazid effects (eg, peripheral neuropathy, encephalopathy, hepatotoxicity) and pyridoxine supplementation should be initiated.<sup>2</sup><br><br>The mechanisms of these potential interactions are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prothionamide [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199302671. Accessed November 23, 2016.</p>\n<p>2. Protionamide [WHO Public Assessment Report part 4]. Available at: http://apps.who.int/prequal/whopar/whoparproducts/TB239part4v02.pdf. Accessed February 2, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11096":"<p><b>Title</b> QTc-Prolonging Agents (Highest Risk) / Hydroxychloroquine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Hydroxychloroquine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Multiple reported cases, but no apparent mechanism or confirmatory studies </p> \n<p><b>Patient Management</b> Avoid concomitant use of hydroxychloroquine and drugs known to prolong the QTc interval.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Highest Risk) Interacting Members</b> Ajmaline, Amiodarone, Anagrelide, Arsenic Trioxide, Artemether, Asenapine, Astemizole, Bepridil, Cisapride, Citalopram, Deutetrabenazine, Disopyramide, Dofetilide, Domperidone, Dosulepin, Dronedarone, Eliglustat, FLUoxetine, Flupentixol, Halofantrine, Ibutilide, Iloperidone, Lopinavir, Lumefantrine, MiFEPRIStone, Nilotinib, Paliperidone, Pimavanserin, Pimozide, Pipamperone [INT], Procainamide, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ribociclib, Sotalol, Sparfloxacin, Sulpiride, Terfenadine, Tetrabenazine, Thioridazine, Toremifene, Vandetanib, Vemurafenib, Vernakalant, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Several case reports demonstrate an association between hydroxychloroquine use and QT interval prolongation and/or torsades de pointes.<sup>1,2,3,4,5</sup> Reported cases have been described in patients who took an intentional overdose of hydroxychloroquine,<sup>1</sup> in patients taking multiple quinine derivatives simultaneously (ie, hydroxychloroquine, quinine sulfate, and tonic water containing quinine),<sup>2</sup> and in patients with altered hydroxychloroquine elimination due to underlying renal or hepatic impairment.<sup>3,4,5</sup> <br><br>The hydroxychloroquine product labeling recommends avoiding the use of hydroxychloroquine in combination with other drugs that prolong the QT interval due to the increased risk of QT-interval prolongation and/or torsades de pointes.<sup>6</sup> Patients with renal or hepatic dysfunction may be at a higher risk for these potentially life-threatening toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ten Broeke R, Mestrom E, Woo L, Kreeftenberg H. Early treatment with intravenous lipid emulsion in a potentially lethal hydroxychloroquine intoxication. <i>Neth J Med</i>. 2016;74(5):210-214. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27323674\">[PubMed 27323674]</a></p>\n<p>2. Sheehan ET, Frizzell JD, Gabaldon J, West MB. Quinine and the ABCs of long QT: A patient's misfortune with arthritis, (alcoholic) beverages, and cramps. <i>J Gen Intern Med</i>. 2016;31(10):1254-1257. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27173501\">[PubMed 27173501]</a></p>\n<p>3. Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. <i>Clin Toxicol (Phila)</i>. 2006;44(2):173-175. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16615675\">[PubMed 16615675]</a></p>\n<p>4. Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. <i>J Clin Rheumatol</i>. 2013;19(5):286-288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23872551\">[PubMed 23872551]</a></p>\n<p>5. O'Laughlin JP, Mehta PH, Wong BC. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine [published online July 12, 2016]. <i>Case Rep Cardiol</i>. doi:10.1155/2016/4626279. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27478650\">[PubMed 27478650]</a></p>\n<p>6. Plaquenil (hydroxychloroquine) [prescribing information]. St. Michael, Barbados: Concordia Pharmaceuticals Inc; January 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11097":"<p><b>Title</b> QTc-Prolonging Agents (Moderate Risk) / Hydroxychloroquine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Hydroxychloroquine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Multiple reported cases, but no apparent mechanism or confirmatory studies </p> \n<p><b>Patient Management</b> Avoid concomitant use of hydroxychloroquine and drugs known to prolong the QTc interval.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Moderate Risk) Interacting Members</b> Azithromycin (Systemic), Bedaquiline, Benperidol, Ceritinib, Chloroquine, ChlorproMAZINE, Ciprofloxacin (Systemic), Clarithromycin, Clofazimine, CloZAPine, Crizotinib, Delamanid, Dolasetron, Droperidol, Efavirenz, Erythromycin (Systemic), Escitalopram, Flecainide, Gadobenate Dimeglumine, Gemifloxacin, Goserelin, Granisetron, Haloperidol, Inotuzumab Ozogamicin, Lenvatinib, Leuprolide, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lofexidine, Mequitazine, Methadone, Midostaurin, Moxifloxacin (Systemic), Ofloxacin (Systemic), OLANZapine, Ondansetron, Osimertinib, Panobinostat, PAZOPanib, Pentamidine (Systemic), Pilsicainide, Piperaquine, Primaquine, Probucol, Propafenone, RisperiDONE, Roxithromycin, Saquinavir, Sodium Stibogluconate, Telavancin, Telithromycin, Terlipressin</p>\n</div> \n<p><b>Discussion</b> Several case reports demonstrate an association between hydroxychloroquine use and QT interval prolongation and/or torsades de pointes.<sup>1,2,3,4,5</sup> Reported cases have been described in patients who took an intentional overdose of hydroxychloroquine,<sup>1</sup> in patients taking multiple quinine derivatives simultaneously (ie, hydroxychloroquine, quinine sulfate, and tonic water containing quinine),<sup>2</sup> and in patients with altered hydroxychloroquine elimination due to underlying renal or hepatic impairment.<sup>3,4,5</sup> <br><br>The hydroxychloroquine product labeling recommends avoiding the use of hydroxychloroquine in combination with other drugs that prolong the QT interval<sup>6</sup> due to the increased risk of QT-interval prolongation and/or torsades de pointes. Patients with renal or hepatic dysfunction may be at a higher risk for these potentially life-threatening toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ten Broeke R, Mestrom E, Woo L, Kreeftenberg H. Early treatment with intravenous lipid emulsion in a potentially lethal hydroxychloroquine intoxication. <i>Neth J Med</i>. 2016;74(5):210-214. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27323674\">[PubMed 27323674]</a></p>\n<p>2. Sheehan ET, Frizzell JD, Gabaldon J, West MB. Quinine and the ABCs of long QT: A patient's misfortune with arthritis, (alcoholic) beverages, and cramps. <i>J Gen Intern Med</i>. 2016;31(10):1254-1257. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27173501\">[PubMed 27173501]</a></p>\n<p>3. Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. <i>Clin Toxicol (Phila)</i>. 2006;44(2):173-175. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16615675\">[PubMed 16615675]</a></p>\n<p>4. Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. <i>J Clin Rheumatol</i>. 2013;19(5):286-288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23872551\">[PubMed 23872551]</a></p>\n<p>5. O'Laughlin JP, Mehta PH, Wong BC. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine [published online July 12, 2016]. <i>Case Rep Cardiol</i>. doi:10.1155/2016/4626279. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27478650\">[PubMed 27478650]</a></p>\n<p>6. Plaquenil (hydroxychloroquine) [prescribing information]. St. Michael, Barbados: Concordia Pharmaceuticals Inc; January 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11098":"<p><b>Title</b> Deflazacort / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of strong CYP3A4 inducers with deflazacort.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> According to deflazacort prescribing information, exposure to the deflazacort active metabolite, 21-desDFZ, was reduced by approximately 95% following administration of the strong CYP3A4 inducer rifampin.<sup>1</sup><br><br>The likely mechanism for this interaction is increased CYP3A4-mediated metabolism of the active 21-desDFZ metabolite, which is a substrate for CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Emflaza (deflazacort) [prescribing information]. Northbrook, IL: Marathon Pharmaceuticals, LLC; February 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11099":"<p><b>Title</b> Deflazacort / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of moderate CYP3A4 inducers with deflazacort.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> According to deflazacort prescribing information, exposure to the deflazacort active metabolite, 21-desDFZ, was reduced by approximately 95% following administration of the strong CYP3A4 inducer rifampin.<sup>1</sup> As a result, concurrent use of deflazacort with strong or moderate CYP3A4 inducers should be avoided.<br><br>The likely mechanism for this interaction is increased CYP3A4-mediated metabolism of the active 21-desDFZ metabolite, which is a substrate for CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Emflaza (deflazacort) [prescribing information]. Northbrook, IL: Marathon Pharmaceuticals, LLC; February 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}